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         Osteoporosis is characterized by reduced skeletal mass and deterioration of the 
microachitecture of the skeleton. Consequently, skeletal fragility and risk of fracture 
increase (Anonymous 1993). Thirty percent of 65–70-year-old women have 
osteoporosis, and after the age of 80 its prevalence increases up to 70 %. 
Postmenopausal women with osteoporosis seem to be at an increased risk of 
cardiovascular events. Furthermore, the deterioration of oral health, as shown by 
attachment loss of teeth, is proportional to the severity of osteoporosis. Osteoporosis 
can be treated with many different forms of medication, but data on the efficacy and 
safety of estrogen treatment comes mainly from early postmenopausal women.  
          We randomized 90 elderly osteoporotic women between 65 and 80 years of age 
to receive hormone therapy (HT) (a continuous combination of 2 mg oral estradiol 
plus 1 mg norethisterone acetate) or 10 mg of alendronate daily or their combination 
for two years and compared the treatments with regard to their effects on bone 
mineral density (BMD) and turnover, and two surrogate markers of the risk of 
cardiovascular diseases (CVDs), C-reactive protein (CRP) and E-selectin, as well as 
oral health. The effect of HT on health-related quality of life (HRQoL) was studied in 
a population-based cohort of 1663 postmenopausal women, mean age 68 years, out of 
which 585 women were estrogen users and 1078 were non-users. 
BMD was measured by dual-energy X-ray absorptiometry (DXA) at 0, 12 and 
24 months. Urinary N-telopeptide (NTX) of type I collagen, a marker of bone 
resorption, and serum aminoterminal propeptide of human type I procollagen (PINP), 
a marker of bone formation, were assayed every six months of treatment. Two 
surrogate markers of CVD risk, serum CRP and E-selectin, were assayed at 0, 6, and 
12 months. Dental, periodontal and intra- and extraoral status, saliva analyses, 
panoramic tomography of the jaws, buffering capacity, oral yeasts and gingival 
crevicular fluid (GCF) matrix metalloproteinase (MMP)-8 levels were studied to 
evaluate oral health status and for mouth symptoms a structured questionnaire was 
used. The HRQOL was measured by means of a generic, comprehensive, 
15-dimensional, standardized, self-administered questionnaire. 
Lumbar spine BMD increased similarly in all treatment groups, ranging from 
6.8 % to 8.4 % at 12 months and from 9.1 % to 11.2 % at 24 months. Only HT 
increased femoral neck BMD significantly at both 12 (4.9 %) and 24 months (5.8 %). 
At the latter time point the HT group differed significantly from the other groups 
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(+3.3 % for the alendronate group at 12 months; + 2.7 % for the combination group at 
24 months). HT reduced bone marker levels of NTX by 60.2-62.7 %, this being 
somewhat less than that with alendronate alone (72.4-76.1 %, p=0.047) or the 
combination (78.1-80.4 %, p<0.0001-0.0069), and the reductions in PINP levels were 
53.6-59.8%, 73.0-75.0% (p<0.001) and 67.0-71.5% (p<0.0001), respectively. 
Oral HT increased serum CRP levels by 76.5% at 6 months (p<0.001) and by 
47.1% at 12 months (NS). The simultaneous rises in serum sex hormone-binding 
globulin (SHBG) concentrations suggested the changes to be a sign of non-specific 
stimulation of hepatic protein synthesis by HT. Oral HT decreased serum E-selectin 
levels by 24.3 % (p<0.001) at 6 months and 30.0 % (p<0.001) at 12 months. 
Alendronate did not have any effect and did not block the effect of HT on these 
surrogate markers of CVD risk. 
Alendronate caused a decrease in the resting salivary flow rate (19 %, p< 0.05) 
and tended to increase GCF MMP-8 levels. Otherwise, the treatments did not have 
any effect on the parameters of oral health. 
HT significantly improved the HRQoL of elderly postmenopausal women as 
regards the dimensions of usual activities, vitality and sexual activity, but the overall 
improvement in HRQoL was neither statistically significant nor clinically important. 
         In conclusion, in elderly postmenopausal women HT is effective in the treatment 
of osteoporosis, but it does not improve the overall quality of life or oral health. HT 
has divergent effects on markers of the risk of cardiovascular diseases. Given all the 
potential risks of CVD, thromboembolic events and cancer associated with HT, 
bisphosphonates might be the first option when starting the treatment of 




















Osteoporosis is characterized by reduced skeletal mass and deterioration of the 
microachitecture of the skeleton. Consequently, skeletal fragility and risk of fracture 
increase (Anonymous 1993).  
Osteoporosis may lead to especially wrist, vertebrae and hip fractures. After 
menopause estrogen deficiency results in increased bone resorption and a reduction in 
bone mass. Thirty percent of 65–70-year-old women have osteoporosis, and after the 
age of 80 its prevalence increases up to 70 % (Melton 1995), with 62 % of 
osteoporotic women having at least one osteoporotic fracture.  In elderly women, 90 
% of hip fractures are attributable to osteoporosis. Osteoporosis is an underdiagnosed 
and also an untreated disease, which through fractures increases morbidity, mortality 
and loss of independence. 
According to an American cost-benefit analysis, examination and treatment of 
osteoporosis are most profitable when directed to 65–70-year-old people (Black 
1995). Osteoporosis can be treated with many different medications, for example 
bisphosphonates or estrogens, but these treatments have not been compared 
previously in elderly women. 
Recent observations suggest that postmenopausal women with osteoporosis 
are at an increased risk of CVD that is proportional to the severity of osteoporosis at 
the time of diagnosis. Treatment of postmenopausal osteoporosis should therefore 
include consideration of measures to prevent cardiovascular outcomes (Tanko et al 
2005). Consequently, studies in which different treatments of osteoporosis (e.g. HT 
and bisphosphonates) are compared regarding their effects on surrogate markers of 
CVD, are well based.  
Postmenopausal women with osteoporosis are at an increased risk of 
attachment loss of teeth, which risk may be attenuated by the use of estrogen 
replacement therapy (ERT) (Grodstein et al 1998, Payne et al 1999, Ronderos et al 
2000). HT has been reported to ameliorate dry mouth feelings (Laine and Leimola-
Virtanen 1996, Leimola-Virtanen et al 1997, Friedlander 2002, Eliasson et al 2003) 
and increase the salivary flow rate (Laine and Leimola-Virtanen 1996). In an 
osteoporosis study, combination treatment with HT, alendronate and calcium 
significantly increased the salivary flow rate (Yalcin et al 2005).  
The latest evidence from randomized trials has shown several health risks 
related to HT use, with breast cancer and thromboembolic events being the most 
important ones (Hlatky et al 2002, Rossouw et al 2002). Postmenopausal women, 
making a decision on whether or not to use HT, may however consider well-being to 
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be a more important factor than the reported health risks. In recent trials, the impact of 
HT on quality of life has remained unclear. In the heart and estrogen/progestin 
replacement study (HERS) HT had only a limited effect on HRQoL in elderly women 
without vasomotor symptoms (Hays et al 2003).  
Women with severe osteoporosis respond to antiresorptive bisphosphonate 
therapy by increasing BMD. Consequently, the incidence of fractures is decreased by 
40-50%. This decreases pain and results in better mobilisation, social well-being and 
quality of life (Devogelaer 1998, O'Connell 1999, Epstein 2000). 
The purpose of this study was to compare two treatments of osteoporosis with 
different mechanisms of action, i.e. HT and bisphosphonate, alendronate, in elderly 
women, separately and in combination, with respect to their effects on bone, oral 
health, and surrogate markers of cardiovascular diseases, and to examine the effect of 








1.1. Definition of osteoporosis 
Bone remodeling constitutes the resorption of old bone and its replacement with new 
bone. A chronic imbalance in the bone remodeling process, with resorption exceeding 
formation, results in osteoporosis, which is characterized by reduced skeletal mass 
and deterioration of the microachitecture of the skeleton. Consequently, skeletal 
fragility and risk of fracture increase (Anonymous 1993). Osteoporosis is defined by 
WHO criteria as bone mineral density (BMD) 2.5 SD or more below the mean of a 
reference population of young premenopausal women. Osteoporosis is currently 
defined as a skeletal disorder characterized by compromised bone strength 
predisposing a person to an increased risk of fracture (NHI Consensus Development 
Panel on Osteoporosis 2001). Bone strength primarily reflects the integration of bone 
quality and bone density. Bone quality refers to architecture, turnover, damage 
accumulation and mineralization.   
Bone turnover is maintained by two groups of cells. Activated osteoclasts 
wander to a resorption site and dig pits in mineralized matrix by secreting enzymes 
and hydrochloride acid. In the consequent synthesis phase osteoblasts refill the pits 
with new bone, which mineralizes, and a new osteon is completed. Osteoclastic 
activity is regulated by the action of sex steroids, especially estrogens, and local 
factors. Coordination with osteoblasts is normally maintained such that there is no net 
change in bone mass during early adult life (Bell 2001). 
 
1.2. Epidemiology of osteoporosis and fractures 
In the menopause, estrogen deficiency results in increased bone resorption and a 
reduction in bone mass. Thirty percent of 65–70-year-old women have osteoporosis, 
and after the age of 80 its prevalence increases up to 70 % (Melton 1995), with 62 % 
of osteoporotic women having at least one fracture. Vertebral fractures are the most 
common osteoporotic fracture, with one in every three women experiencing it in their 
lifetime (Cummings and Nevitt 1989), but 50 % of them occur without symptoms. 
The most serious fracture is hip fracture, which carries a high risk of mortality, with 
10-20 % of women dying earlier than expected for age within the first year after the 
fracture (Cummings and Melton 2002). The lifetime risk of hip fracture at 50 years of 
age is 17.5% for women, and 6 % for men (Lips 1997). The incidence of wrist 
fracture increases up to the age of 60-65 years and it plateaus thereafter. Most hip 
fractures occur after the age of 70 years, when age-associated fragility, falls, and bone 
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loss are the most important risk factors in the development of such fractures (Hui et al 
1988). Because the world´s population is ageing, the frequency of hip fractures is 
increasing by 1-3 % per year in the most areas of the world (Cummings and Melton 
2002).  
 Age is an independent risk factor for fractures. A reduction of 1 SD in BMD 
(Fig.1), and ten years’ ageing, each double the risk of fracture independently of one  
another. 
In Finland there are estimated to be 400 000 patients with osteoporosis, and 
every year there are 40 000 new fractures, 7000 of them being hip fractures (Alhava 
2004). 
 
FIGURE 1. Relationship between bone mineral density (BMD) and fracture risk based on a 
doubling of risk with each SD decrease in BMD (most epidemiological studies have reported 
relative risks between 1.5 and 2.5 per SD of BMD). A relative risk of 2.0 indicates the risk is 
twice as high compared with the reference value. T scores between -1.0 and -2.5 indicate 
osteopenia, and values lower than -2.5 indicate osteoporosis. 
 
1.3. Assessment of bone  
1.3.1. Bone mineral density 
Dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography 
(QCT) are the best biophysical ways to assess bone in clinical practice. DXA allows a 
greater variety of measurement sites. For repeated measurements, DXA provides good 
precision (error 1-2%) at a low radiation burden (<1 µSv), stable calibration and a 
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short scanning time (2-5min).  Repeated measurements permit estimation of the rate 
of bone loss in untreated patients and give useful information about treatment effect. 
The metabolically more active trabecular bone in the lumbar spine changes faster after 
menopause and during treatments of osteoporosis than the cortical bone in the hip. 
Thus, for repeated measurements the lumbar spine appears to be the most sensitive 
skeletal site, but it is more sensitive than the hip to artefacts (Wahner 1989). In 
clinical practice DXA is the most commonly used technique for measurement of areal 
bone density (g/cm²). Despite its many advantages, there are some problems with 
DXA. Besides the vertebral body the measurement also captures the arches and 
spinous processes. Aortic calcification, radio-opaque contrast media, metallic objects, 
distribution of fat tissue, previous vertebral fractures, scoliosis, osteomalacia or 
osteoarthrosis may affect the results at the lumbar spine (Kröger and Reeve 1998). 
QCT is the only alternative to measure true volumetric bone density (g/cm³), 
and trabecular and cortical bone areas can be measured separately. Availability, 
expenses and higher radiation dose (50 µSv or more) are the limits of this technique in 
clinical practice (Wahner 1989). 
 
1.3.2. Bone turnover markers 
There are several biochemical markers that can be used to quantify bone metabolism. 
These assays measure in serum or in urine enzymes or matrix proteins synthesized or 
degraded by bone cells. They can be divided into those measuring bone formation and 
those quantifying bone resorption. 
 
1.3.2.1. Markers of bone formation  
 
Alkaline phosphatase 
The common form of alkaline phosphatase (ALP) is a cell-membrane-associated 
enzyme expressed by the liver, bone, kidneys and placenta. In adults the liver and 
bone are the major sources of ALP. In bone, ALP is derived from osteoblasts and their 
precursors, and it has a role in bone mineralization. ALP may increase the local 
concentration of inorganic phosphate, destroy local inhibitors of crystal growth, 
transport phosphate and act as a calcium-binding protein. To be used as a marker of 
bone formation, the bone-specific isoform (bone ALP) has to be distinguished from 
the liver-specific-isoform (Behr and Barnert 1986). 
Osteocalcin 
Human osteocalcin (OC) is a 49-residue polypeptide of γ-carboxyglutamic acid (Gla), 
which is synthesized by mature osteoblasts during the mineralization phase of bone 
remodeling in a vitamin K-dependent carboxylation process. Vitamin D modulates the 
OC-gene (Stein et al 1996). OC is also found in other calcified tissues such as dentin 
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and calcified cartilage. In the bone it forms about one per cent of the organic matrix. 
OC is released into the circulation during the bone formation, and it is filtered in the 
kidneys. However, as OC is incorporated into bone extracellular matrix, some of the 
circulating OC might originate from degrading bone. Thus circulating OC may reflect 
bone turnover rather than bone formation alone (Riggs et al 1986).  
Type I collagen propeptides 
Type I collagen is synthesized by osteoblasts from type I procollagen precursor 
proteins. These precursors have large extension domains at both ends. While type I 
collagen is being synthesized, the type I aminoterminal and carboxyterminal 
propeptides, PINP and PICP respectively, are enzymatically removed and released 
into the circulation (Calvo et al 1996). As bone is the major organ synthesizing type I 
collagen, PINP and PICP reflect bone formation (Delmas 1992, Ebeling et al 1992). 
PINP and PICP are degraded in the liver and elevated serum levels have been 
measured in patients with chronic liver disease (Guanabens et al 1994). PINP and 
PICP can be measured by immunoassays (Melkko et al 1990, Melkko et al 1996). 
 
1.3.2.2. Markers of bone resorption 
 
Bone resorption markers reflect collagen degradation and proteolysis of collagen by 
osteoclasts. 
Pyridinoline cross-links 
Collagen molecules are held together by hydrogen bonds and pyridinium cross-links. 
When collagen degrades, these cross-links (pyridinoline [Pyr] and deoxypyridinoline 
[Dpy]) are released into the circulation, and then excreted into urine. Because bone is 
the major reservoir of type I collagen, and it turns over faster than most major 
connective tissues, pyridinolines in adult urine are mostly derived from bone and thus 
reflect bone resorption (Eyre 1997).  
Tartrate-resistant acid phosphatase 
Tartrate-resistant acid phosphatase is an enzyme, the 5b-isoform (TRACP5b) of 
which is expressed in high amounts in osteoclasts. During bone degradation 
TRACP5b is released into the circulation. It has been shown to be present in elevated 
concentrations in patients with metabolic bone diseases. It seems to be a relatively 
sensitive and specific marker of bone resorption. It reflects both cathepsin-K- and 
MMP-mediated bone degradation. During bisphosphonate therapy serum TRACP5b 
concentrations decrease (Halleen et al 2001).  
Cross-linked telopeptides of type I collagen 
When type I collagen is degraded, it is split into several fragments. Cathepsin-K and 
MMPs take part in this process. Two fragments have been characterized in the 
carboxyterminal end of type I collagen. The first is a cross-linked carboxyterminal 
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telopeptide of type I collagen (ICTP) and the second a C-terminal cross-linked 
telopeptide of type I collagen (CTX). ICTP is a larger molecule than CTX (Garnero et 
al 2003). There is another type I collagen telopeptide (NTX) in the aminoterminal 
end. It is thought that cathepsin-K releases mostly CTX and NTX, and MMPs ICTP 
(Garnero and Delmas 1998, Garnero et al 2003). CTX and NTX can be measured in 
urine or serum by immunoassays (Risteli et al 1993). These markers have been shown 
to be present in elevated concentrations in patients with metabolic and metastatic bone 
diseases (Tähtelä and Tholix 1996, Fohr et al 2003, Garnero et al 2003). During 
antiresorptive treatment, serum and urinary concentrations of CTX and NTX decrease 
(Christgau et al 2000). 
Changes in bone turnover can be measured by means of the above mentioned 
biochemical markers within a few months of beginning treatment.  
 
2. Consequences of menopause  
 
2.1. Climacteric symptoms 
Menopause results in a decrease in serum estradiol concentrations and cessation of 
natural menstruation. It occurs on average at the age of 51 years (range 45-55 years) 
in Western countries (Oldenhave et al 1993). Estrogen deficiency due to ovarian 
failure causes climacteric symptoms, such as hot flushes, night sweats, irritability, 
depression, headache, palpitations, sleeping disorders and vaginal dryness (Stearns et 
al 2002).  At least 75 % of all women have these symptoms at menopause, usually for 
two years, and 25-50% of symptomatic women have them for more than 5 years 
(Oldenhave and Netelenbos 1994); 20 % of women have them for 15 years (Stearns et 
al 2002).  Among elderly women in the HERS trial (mean age 67 years) 15.7% still 
had hot flushes. Despite of the high prevalence of the symptoms, their 
pathophysiology remains mainly unknown. A decline in estrogen concentrations 
might lead to alterations in brain neurotransmitters and to instability in the 
hypothalamic thermoregulatory set - point (Stearns et al 2002). The symptoms are 
more common in smokers and in underweight and sedentary women (Stearns et al 
2002). 
 Urogenital symptoms caused by estrogen deficiency and atrophic urogenital 
epithelia are complained of by 10-40 % of postmenopausal women (Cardozo et al 
1998). The most common complaints are vaginal discharge, itching, burning, 
dyspareunia, and recurrent urinary and vaginal infections (Raz and Stamm 1993, 
Cardozo et al 1998). 
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2.2. Effects on bone  
The velocity of bone loss increases during ageing. BMD begins to decrease in both 
sexes before 30-35 years of age, but before menopause the net loss is slow as a result 
of slow remodeling in estrogen-sufficient women. In bone, estrogens inhibit bone 
resorption, to a great extent through receptors in osteoblasts, by down-regulating the 
expression of bone- resorbing cytokines, such as interleukins (IL)-1α, IL-1β, IL-6 and 
tumor necrosis factor-α (TNF-α). Lack of estrogens leads to increased activity of these 
cytokines. In menopause, circulating estrogen concentrations fall rapidly and 
osteoclastic activity accelerates, outstripping the attempts of osteoblasts to keep pace. 
Especially in trabecular bone the interval between remodeling cycles shortens and at 
the osteon level both bone resorption and formation are accelerated, resorption more 
than formation (Riggs et al 2002). In late postmenopausal women (age more than 60 
years), low E2 levels are associated with low trabecular and cortical BMD (Khosla et 
al 2005). Similar to findings in men, the threshold for estrogen deficiency in cortical 
bone in women appears to be lower than that in trabecular bone (Khosla et al 2005).  
BMD decreases by approximately 1.5 % each year during the first 3 years after 
menopause, followed by an annual loss of 0.3-0.4 % after that (Komulainen et al 
1999). The net result is bone loss of up to 50 % in trabecular bone and 30 % in 
cortical bone by age 80 in women (Seeman 2004). Bone resorption markers increase 
in menopause, and increased levels seem to be associated with an increased fracture 
risk in elderly women (Looker et al 2000).  
 
2.3. Effects on risks of cardiovascular diseases and their surrogate markers 
CVDs are rare in premenopausal women compared with age-matched men (Barrett-
Connor and Bush 1991, Isles et al 1992), but after onset of menopause the occurrence 
of CVD events rises and by the age of 70 years it is equal in women and men (Carr 
2003).  
 The concentrations of total cholesterol, LDL, and VLDL cholesterol as well as 
triglycerides seem to increase with age in both sexes. In longitudinal studies 
atherogenic changes in lipid and lipoprotein profiles have been observed within two 
years preceding the menopause (Jensen et al 1990, Do et al 2000). Increases of both 
total and LDL cholesterol concentrations have been observed during menopause, and 
a shift to smaller and denser and potentially more atherogenic LDL particles has been 
related to menopause (Campos et al 1988), but data on HDL cholesterol have been 
inconsistent. A decline in HDL2 and a rise in HDL3 may result in an unfavorable net 
effect (Matthews et al 1994). 
 The risk of impaired glucose metabolism, and abdominal obesity, increase 
after menopause. They have been shown to be independent risk factors for coronary 
heart diseases (CHD), cardiovascular mortality and future diabetes (Carey et al 1997, 
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Wajchenberg 2000, Hu et al 2004). Hypertension and endothelial dysfunction are also 
likely to develop after menopause, increasing the risk of CVDs (Gambacciani et al 
2002). 
Inflammatory processes play a pivotal role in the pathogenesis of 
atherosclerosis and they mediate atheroma development from initial leukocyte 
recruitment to the eventual rupture of an unstable atherosclerotic plaque (Blake and 
Ridker 2001, Ambrose and Martinez 2002). Elevated plasma levels of markers of the 
inflammatory cascade (P-selectin, interleukins (IL), tumor necrosis factor alpha 
[TNFα], soluble intercellular adhesion molecule-1, and CRP) seem to predict plaque 
rupture. Synthesis of CRP in the liver is induced by IL-1 and –6, and minimal changes 
can be measured immunochemically with highly sensitive assay using monoclonal 
antibodies. It seems to be the most powerful inflammatory marker of future 
cardiovascular risk, and to have a direct proinflammatory effect (Ridker et al 1998, 
Lagrand et al 1999, Ridker et al 2000, Blake and Ridker 2001, Danesh et al 2004). At 
menopause the plasma levels of E-selectin increase (Kennedy et al 1999), but ageing 
in itself does not have any effect on CRP levels in postmenopausal women (Sites et al 
2002). Final occlusion of an artery results when circulating macrophages and 
lymphocytes are trapped from on the vascular wall by adhesion molecules, e.g. E-
selectin (Gearing and Newman 1993). Thus, E-selectin may play a role in the 
development of atherosclerosis (Farzati et al 2002), and high plasma levels may be 
associated with an increased risk of CVD. 
Plasma SHBG is sythetized in the liver and it regulates the bioavailable 
fraction of steroids and also their access to target cells (Kahn et al 2002). Estrogen 
and thyroid hormones increase, while androgens decrease the synthesis of SHBG 
(Nachtigall et al 2000). Hyperinsulinemia, insulin like growth factor-1 and 
hyperandrogenism are associated with low SHBG levels (Hogoveen et al 2002, 
Kalme et al 2003). Decreased levels of SHBG are explained by estrogen deficiency 
after menopause (Sarrel 2002). 
Calcification is an active process in CVDs, especially in coronary arteries. 
Epidemiological evidence has shown the coexistence of vascular calcification with 
both atherosclerosis and osteoporosis, and hyperlipidemia and atherogenic 
phospholipids in vascular calcification. Many bone regulatory factors have been 
shown to be present in calcified atherosclerotic lesions, and regulate mineralization in 
both bone and vasculature and may account for the co-existence of osteoporosis and 
atherosclerotic calcification (Tintut and Demer 2001). In the placebo group in the 
Multiple Outcomes of Raloxifene Evaluation (MORE) trial an inverse association 
between BMD and the severity of atherosclerosis was shown in postmenopausal 
women (Tanko et al 2005). Osteoporotic women were at an increased risk of 
cardiovascular events, both coronary events and stroke. The association was not 
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explained by the usual surrogate markers of CVD, e.g. CRP or lipids, but as linking 
factors the authors suggested the regulators of bone turnover, e.g. matrix GLA 
protein, osteoprotegerin, and osteocalcin, proinflammatory cytokines such as IL-6 and 
TNF-α, oxidized lipids or NO synthase (Tanko et al 2005).  
 
2.4. Effects on oral health 
The oral status of premenopausal women is better than that of menopausal women 
(Yalcin et al 2005). Estrogen deficiency after menopause may cause oral health 
problems, e.g. tooth loss (Grodstein et al 1998). Xerostomia and salivary gland 
hypofunction (SGH) increase in the menopausal period and are prevalent in elderly 
populations, more in women than in men, causing much discomfort and even 
difficulties in eating (Närhi et al 1999). Buccal mucosa and salivary gland tissue 
contain estrogen receptors and are thus estrogen-responsive tissues (Leimola-Virtanen 
et al 2000). Dry mouth symptoms caused by insufficient salivary secretion due to 
estrogen deficiency, concomitant diseases and medication are an increasing oral 
health problem with advanced age. The salivary flow rate has been shown to decrease 
in the menopausal period (osteoporotic women aged 50.7 years compared with non-
menopausal control women aged 42.4 years) but to increase significantly (p=0.03) 
after osteoporosis combination treatment of HT (conjugated estrogen (CEE) 
0.0625mg plus MPA 5mg) with alendronate and calcium supplementation in early 
postmenopausal women (Yalcin et al 2005). Burning or painful mouth is a condition 
that elicits a burning sensation in the oral cavity. When no obvious somatic pathology 
can be found, the condition is called burning mouth syndrome (BMS). Among 50- to 
58-year-old women, 8.2 % suffer from BMS and 19.9 % from dry mouth symptoms. 
Despite of HT, climacteric symptoms, smoking and antidepressants are risk factors for 
BMSs, which are a common complaint in elderly women (Tarkkila et al 2001). 
Osteoporosis correlates with the loss of alveolar bone and increases the risk of 
attachment loss of teeth (Wactawski-Wende et al 1996, Payne et al 1999, Reinhardt et 
al 1999, Wactawski-Wende et al 2005). 
Oral health status can be evaluated by dental, periodontal and intra- and extra-
oral status, saliva and gingival crevicular fluid tests, panoramic tomography of the 
jaws (OPTG), by measuring the buffering capacity of the saliva and by looking for 
oral yeasts. 
 
2.5. Effects on health-related quality of life 
Estrogen deficiency at menopause causes multiple physiologic changes, which affect 
quality of life (QoL) with the interplay of different biological, cultural, social and 
psychological factors. Standardized questionnaires are used to study health- related 
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quality of life (HRQoL). Generic HRQoL tests cover all aspects of health, whereas 
disease-specific tests concentrate on the complaints typical of some particular disease. 
Menopausal women have been found to have worse QoL scores than younger 
women, with a 3.5-fold risk of psychosocial impairment, a 5.7-fold risk of physical 
disorders, a 3.2-fold risk of sexual disorders and a 10.6-fold risk of vasomotor 
disorders (Blumel et al 2000). Menopause is associated with loss of libido, 
dyspareunia, and anorgasmia (Bachmann 1995). Forty-six percent of women with hot 
flushes report a reduced libido (Chiechi et al 1997). In other studies the effects of 
menopause on QoL have been of minor importance (Avis and McKinlay 1991, 
Ekström and Hovelius 2000). 
In elderly women, quality of life scores have been reported to decline 
significantly as regards physical function, mental health, and energy/fatigue over 3 
years (HERS) (Hlatky et al 2002). 
At least 75 % of all women have hot flushes at menopause, reducing the QoL, 
and 25-50 % have them for more than 5 years (Oldenhave and Netelenbos 1994). In 
particular, underweight and sedentary women with little or no exercise, and smokers, 
are at an increased risk of hot flushes (Stearns et al 2002). Symptoms and complaints 
differ between populations and cultures, and a low educational level and low 
socioeconomic status are risk factors for hot flushes (North American Menopause 
Society 2004).  
Questionnaires   
The most frequently used generic measure in HT studies has been the 
Nottingham Health Profile (NHP). Other options have been 15D, RAND-36, Short 
Form Survey (SF)-36, Sickness Impact Profile (SIP), Medical Outcomes Study 
(MOS), Health Utility Index (HUI) and EuroQoL (EQ-5D) (Hunt et al 1981, 
MacKeigan and Pathak 1992). The Women´s Health Questionnaire and Menopause 
Rating Scale are disease-specific measures, designed for climacteric symptoms. The 
generic HRQoL measures are better established than the disease-specific measures, 
but the disadvantage of the generic tests is their lack of sensitivity to health changes in 
specific conditions. They may detect benefits and adverse effects of treatments that 
are not anticipated. The disease-specific measures are considered more acceptable, but 
their validity is not as well established (Sintonen et al 2003). 
The 15D questionnaire is a generic self-administered and standardized HRQoL 
measure, which is well documented in terms of reliability, validity, discriminatory 
power and responsiveness to health changes (Kauppinen et al 1998, Sintonen 2001). It 
contains 15 multiple choice questions. Each question represents one health-related 
dimension, concerning mobility, vision, hearing, breathing, sleeping, eating, speech, 
elimination, usual activities, mental function, discomfort and symptoms, depression, 
distress, vitality and sexual activity. NHP is a generic self-administered measure with 
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established reliability. It consists of statements on how a subject feels or functions. 
The 38 statements are divided into six dimensions covering energy, sleep, pain, 
emotional reactions, social isolation and physical mobility (Hunt et al 1981).  The 
NHP and 15D questionnaires gave similar results in assessment of HRQoL of women 
on HT (Sintonen et al 2003). 
Based on the structure of the questionnaire, HRQoL measures can be 
categorized into profiles and single index measures. The profiles comprise multiple 
dimensions representing different aspects of health. Every dimension is scored 
separately (MacKeigan and Pathak 1992). The scores from all the dimensions can be 
summed up to obtain a single index number varying from 0 (death) to 1 (full health) 
(Brazier et al 1998). 
 
3. Hormone therapy 
 
3.1. General principles 
Menopausal complaints have been treated with estrogens, alone or in combination 
with progestogen, for more than 50 years (Barrett-Connor 2003). Only estrogen is 
needed to alleviate climacteric symptoms, but with an intact uterus progestin is 
needed because of the increased risk of hyperplasia and endometrial cancer (Manson 
and Martin 2001). Estrogen regimens can be oral, transdermal, intranasal or 
subcutaneous. Progestogen is given sequentially or continuously either orally, 
transdermally or via the intrauterine route (North American Menopause 2004). In 
Finland 22 % of all postmenopausal women used HT in 2002. Most commonly, use 
was at 55-56 years of age (Salmi et al 2004). Between Finnish HT users and non-
users there are no socioeconomic differences under 55 years of age, but older 
educated women use HT more frequently than less educated women (Topo et al 
1999). 
In the United States 35-40 % of postmenopausal women of 50-74 years of age 
use HT, but 50-60 % use it for less than one year (Keating et al 1999, Ettinger. 2003). 
Only 20 % of women use HT for 5 years or more in the USA (Brett and Madans 
1997). HT use is common among well educated postmenopausal women. Cultural and 
socio-demographic factors, such as region and education, may be more strongly 
associated with use of HT than clinical factors (Keating et al 1999, Genazzani et al 
2002). In Finland, HT use has decreased by 12 % for estradiol-only preparations, by 




3.2. Effects on bone  
Estrogen plays pivotal roles in the function and maintenance of the skeleton, including 
the bone-forming osteoblasts. The functions of E2 are largely mediated through two 
distinct estrogen receptor (ER) isoforms, ERalpha and ERbeta, both of which are 
expressed in osteoblasts (Monroe et al 2003). Estrogen reduces bone resorption by 
decreasing serum levels of osteoclast-stimulating cytokines, interleukins and tumor 
necrosis factor-α, and by up-regulating transforming growth factor (TGF)-ß, which 
inhibits bone resorption by decreasing the activity of osteoclasts and by increasing 
their apoptosis (Manolagas 2000). Estrogens prevent postmenopausal bone loss, 
improve bone density by 5-10 % over 1-3 years (Genant et al 1989, Lindsay and 
Tohme 1990, Schneider et al 1997, Recker et al 1999, Wells et al 2002), and decrease 
the risk of vertebral and non-vertebral fractures, including hip fractures, in 
populations of postmenopausal women not selected on the basis of osteoporosis 
(Rossouw et al 2002, Cauley et al 2003). They also decrease the risk of vertebral 
fractures in established osteoporosis (Lufkin et al 1992). In a meta-analysis of 
randomized controlled trials of HT a statistically significant reduction in non-vertebral 
fractures was noted (Torgerson and Bell-Syer 2001). In a cohort study, hormone 
therapy effectively prevented hip fractures among women older than 75 years (Cauley 
et al 1995). In the WHI population, not selected as regards BMD or fracture history, 
HT reduced the risk of vertebral, hip and non-vertebral fractures in women with a 
mean age 63 years, the absolute risk reductions per 10 000 person-years being 5 fewer 
hip, 18 fewer wrist/lower arm and 47 fewer total fractures (Cauley et al 2003). 
Estrogens combined with progestins may increase vertebral BMD more than 
estrogens alone, with the effect being most pronounced during the first two years of 
HT (Christiansen and Riis 1990, Anonymous 1996, Speroff et al 1996). Some 
progestins have a more powerful effect on bone than others (Hosking et al 1998).  
 
3.3. Cardiovascular benefits and risks 
Estrogen has several favorable effects, that may be protective against CVD, serum 
lipids and lipoproteins having been most widely studied (The Writing Group for the 
PEPI trial 1995, Godsland 2001, Davison and Davis 2003). Epidemiological data have 
shown a close association between serum lipoproteins and CVD risk (Rich-Edwards 
et al 1995). High levels of LDL and low levels of high density lipoproteins (HDL) are 
regarded as predictors of such risks (Margolis 1990). Estrogens decrease  serum levels 
of total and LDL cholesterol, lipoprotein (Lp(a)), and increase that of HDL 
cholesterol (Lobo 1991, Barrett-Connor and Miller 1993). The lipid and lipoprotein 
responses to HT depend on the type and dose of estrogen and the route of 
administration (Godsland 2001). 
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Estrogens have a favorable effect on the vascular wall, by increasing the 
production of vasodilatory prostacyclin (Ylikorkala et al 1986, Vane et al 1990) and 
nitric oxide (NO) (Cicinelli et al 1997), which also inhibits platelet aggregation 
(Moncada et al 1991). Endothelin-1 (ET-1) is a vasoconstrictive peptide produced by 
endothelial and smooth muscle cells (Masaki 1993). Estrogens decrease the serum 
levels of ET-1 in postmenopausal women (Ylikorkala et al 1995, Wilcox et al 1997).   
Long-term HT has shown a protective effect on age-related thickening of the intima-
media of carotid artery after the menopause (Tremollieres et al 2000). 
The effects of estrogens on glucose metabolism and insulin sensitivity are 
conflicting (Barrett-Connor and Laakso 1990, Espeland et al 1998, Raudaskoski et al 
1999, Karjalainen et al 2001). In the recent clinical trial CEE tended to have a 
protective effect on the incidence of diabetes (HR 0.88, 95 % CI 0.77-1.01) (Bonds et 
al 2006). 
Oral estrogen plus progestogen treatment has been associated with increased 
levels of CRP (Cushman et al 1999, Ridker et al 1999, van Baal et al 1999, Luyer et 
al 2001, Prelevic et al 2002), although not in all studies (Zanger et al 2000, Oger et al 
2001). In contrast, transdermal HT reduced CRP levels (Vehkavaara et al 2001).  The 
type and route of the estrogen component may be most significant as regards the 
elevations in CRP concentrations, but progestin may also have an influence (Sattar et 
al 1999, Zanger et al 2000). Women using HT orally (Cushman et al 1999, Zanger et 
al 2000, Luyer et al 2001) or transdermally (Oger et al 2001, Vehkavaara et al 2001, 
Farzati et al 2002) are characterized by having 18-35 % lower serum E-selectin levels 
than non-users. Transdermal HT has been reported to have no effect on E-selectin 
levels (Oger et al 2001). 
Oral ERT elevates the concetrations of SHBG (Samsioe 2002), but 
transdermal ET has no effect (Samsioe 2002). The effect of the progestogen on SHBG 
depends on the androgenicity of the treatment. Androgenic progestogens, e.g. NETA, 
decrease the synthesis of SHBG, whereas cyproterone acetate and dydrogesterone 




Table 1. The  effects of estrogens on CVD risk factors 
(↑increase, ↓ decrease, - no change). 
Risk factor    Oral      Transdermal  
C-reactive protein   ↑  ↓, - 
E-selectin    ↓  ↓, - 
Lipids and lipoproteins 
Total cholesterol  ↓↓  ↓ 
LDL cholesterol   ↓↓  ↓ 
 HDL cholesterol   ↑↑  ↑, - 
 Triglycerides   ↑                     ↓, - 
 Lp(a)    ↓  - 
Endothelial cell function 
Prostacyclin   ↑  - 
Nitric oxide   ↑  ↑ 
Endothelin-1   ↓  ↓ 
Endothelium vascular resistance  ↓  ↓ 
Homocysteine    ↓ , -,↑  ↓, - 
Insulin sensitivity   ↑ , -  ↑, - 
 
3.3.1. Coronary heart disease 
In recent studies no cardiovascular benefits, or even adverse effects, have been 
reported in connection with HT (Grady et al 2002, Rossouw et al 2002). In the WHI 
study the risk of CHD in the estrogen group remained unchanged (hazard ratio [HR] 
0.91, 95 % CI 0.75-1.12), but it was increased (HR 1,29, 95 % CI 1.02-1.63) in the 
estrogen-progestin group. On the other hand, the total CVD event rate, including 
stroke, was increased in the estrogen group (HR 1.12, 95 % CI 1.01-1.24) in 




In the WHI study the risk of stroke increased in women with a mean age of 63 years 
in both groups, ERT (HRs 1.39, 95% CI 1.10-1.77) and estrogen-progestin therapy 
group (HRs 1.41, 95% CI 1.07-1.85) (Rossouw et al 2002, The Women's Health 
Initiative Steering, Committee 2004). Estrogens should not be used for secondary 
prevention of stroke (Viscoli et al 2001), since after an ischemic stroke the risk of 
recurrence was increased during the first 6 months (relative risk (RR) 2.3, 95 % CI 
1.1-5.0), but not significantly over 2.8 years (RR 1.1, 95% CI 0.8-1.4). 
 
3.3.3. Venous thromboembolism 
The balance between the coagulation and fibrinolytic systems determines the risk of 
venous thrombosis. Estrogens have a complex effect on hemostatic factors. They 
activate fibrinolysis, but still increase the risk of venous thromboembolism (VTE). 
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The procoagulant changes include increases in factor VII, prothrombin fragments 1 
and 2, resistance to activated protein C and decreases in antithrombin III and protein 
S. On the other hand, the increased D-dimer levels, and reduced levels of fibrinogen 
and plasminogen activator inhibitor-1 suggest increased fibrinolytic activity 
(Grodstein et al 1996, Conard et al 1997, Koh et al 1997, Braunstein et al 2002). 
 Current use of HT is associated with an increased risk of venous thrombosis 
(VTE) (Daly et al 1996). In contrast to peroral HT, the effects of transdermal estrogen 
on hemostatic factors appear to be insignificant with lack of hypercoagulability effect 
(Koh et al 1997, Vehkavaara et al 2001). The results of a case control study suggested 
the odds ratios for VTE in current users of oral and transdermal estrogen replacement 
therapy (ERT) vs. non-users to be 3.5 (95% CI 1.8-6.8) and 0.9 (0.5-1.6), 
respectively. The estimated risk for current users of oral vs. transdermal ERT was 4.0 
(1.9-8.3) (Scarabin et al 2003). Observational studies indicate that postmenopausal 
use of estrogen increases the risk of deep VTE by a factor of 3.6 (95% CI 1.6-7.8) 
(Jick et al 1996). A meta-analysis of studies of estrogen use and risk of VTE showed a 
summary relative risk of 2.14 (Nelson et al 2002), whereas the data from the 3 
randomized controlled trials (RCTs) gave a relative estimate of 3.75 (Humphries and 
Gill 2003). In the HERS trial the risk of VTE was increased by a factor of 2.7 among 
elderly women (mean age 67 yr) assigned to receive estrogen-progestin therapy 
(Manson and Martin 2001). The highest risk is during the first year of use (3.2 
additional events per 10 000 women-years) (Nelson et al 2002, Humphries and Gill 
2003), among women with coagulation abnormalities (Braunstein et al 2002), and 
among women taking high doses of estrogen (Jick et al 1996). After the first year the 
additional events are only 1.2 per 10 000 woman-years (Humphries and Gill 2003).  
 
3.4. Effects on oral health 
Buccal mucosa and salivary gland tissue contain estrogen receptors and might thus be 
estrogen-responsive tissues (Leimola-Virtanen et al 2000). HT has been reported to 
ameliorate dry mouth feelings (Laine and Leimola-Virtanen 1996, Leimola-Virtanen 
et al 1997, Friedlander 2002, Eliasson et al 2003). 
Nearly 32 % of women in the USA aged 65 to 69 years have no teeth. The risk 
of tooth loss is 24 % lower in estrogen users than in non-users. Thus, estrogens may 
reduce tooth loss (Grodstein et al 1996). 
 HT has significantly increased alveolar bone mass compared with placebo, 
and it tended to improve alveolar crest height (Civitelli et al 2002). Severe clinical 
attachment loss of teeth (11.9 % vs.18.6 %) and alveolar bone loss (20.3 % vs. 34 %) 
have been reported to be decreased in HT users in comparison to non-users (Grossi 
1998). 
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Osteoclasts resorb bone by secreting acid and proteolytic enzymes into 
extracellular resorption lacunas. Two major groups of proteinases, MMPs and 
cysteine proteinases, play the greatest role in degradation of the organic matrix, which 
is composed mainly of type 1 collagen (Parikka et al 2001). Estrogens reduce the 
depth of resorption pits by decreasing the organic bone matrix degradation activity of 
mature osteoclasts and by decreasing the activity of cysteine proteinases (Parikka et al 
2001) and MMPs (Liao and Luo 2001).  
 
3.5. Effects on quality of life 
HT has been shown to relieve menopausal symptoms effectively shortly after the start 
of treatment (McNagny 1999, MacLennan et al 2001) and it thereby improves the 
general well-being of early postmenopausal women (Wiklund et al 1992 Daly et al 
1993, Zethraeus et al 1997, Genazzani et al 2002, Sintonen et al 2003). The impact of 
HT on generic HRQoL has not been so widely studied, but the results have been 
promising in early menopause (Wiklund et al 1992, Zethraeus et al 1997, Genazzani 
et al 2002). At menopause, women (mean age 53 years) on transdermal estrogen 
combined with norethisterone acetate experienced improvement in all dimensions of 
the NHP questionnaire, especially as regards sleep and energy dimensions (Wiklund 
et al 1992). In addition, low-dose continuously combined HT has been found to be of 
value in the enhancement of HRQoL (15D) of relatively young postmenopausal 
women (mean age 56 years) for whom the relief of menopausal symptoms and control 
of bleeding are primary objectives of treatment (Ylikangas et al 2005). In more 
elderly women (mean age 62 years) continuously combined estradiol valerate (E2V) 
plus MPA has been found to have a positive impact on all dimensions of the 15D and 
NHP questionnaires, with minimal breakthrough bleeding and limited adverse effects 
(Sintonen et al 2003).  
In the WHI study women assigned to use HT (mean age 63 years) experienced 
fewer sleep disturbances, better physical functioning and less bodily pain than women 
who were assigned to use placebo (RAND-36). The difference was statistically, but 
not clinically significant at one year of treatment, but it disappeared with continuation 
of treatment for an additional two years (Hays et al 2003). 
The HERS trial showed mixed effects, and women without hot flushes at 
entry showed declines in physical measures and those with hot flushes showed 
improvements in emotional measures when assigned to HT (mean age 67 years). The 
HRQoL, measured by means of several questionnaires (RAND, depressive symptoms 
on the Burnam screening scale), was impaired in older women and in those with 
chronic diseases (diabetes, hypertension, chest pain, heart failure). The negative 




 The Collaborative Group on Hormonal Factors in Breast Cancer has reanalyzed about 
90 % of the worldwide epidemiological evidence on the relationship between risk of 
breast cancer and use of HT. 52 705 women with breast cancer and 108 411 women 
without breast cancer were analyzed centrally. Thirty-three percent of the women had 
used HT at some time, and 34% of users had used HT for 5 years or more.. The risk of 
breast cancer seems to increase with duration of HT. This effect is reduced after 
cessation of use of HT and disappears in about 5 years (Anonymous 1997). In the 
WHI study estrogen plus progestin increased the absolute risk of breast cancer by 8 
additional cases per 10 000 person-years (HR 1.26, 95 % CI 1.00-1.59) (Rossouw et 
al 2002). Breast cancers tended to be at a more advanced stage during HT vs. placebo 
at the time of diagnosis (Chlebowski et al 2003). In the estrogen-only arm no 
increased risk of breast cancer was found after seven years’ estrogen use vs. placebo 
(HR 0.80, 95 % CI 0.62-1.04), in exploratory analyses ductal carcinomas were 
reduced in the CEE group (HR 0.71, 95 % CI 0.52-0.99) (The Women's Health 
Initiative Steering, Committee 2006).  
Endogenous and exogenous estrogen is a risk factor as regards endometrial 
cancer (Grady et al 1995). Estrogen promotes the formation of estrogen receptors and 
proliferation of the endometrium whereas progesterone down-regulates these 
receptors and causes secretory changes. This explains why estrogens without 
progestin increase the risk of hyperplasia and in a minor proportion of patients cause 
endometrial cancer (Westhoff et al 2000, Manson and Martin 2001). A meta-analysis 
of 29 epidemiological studies showed a 1.4-fold risk of endometrial cancer with less 
than one year of estrogen use, and a 9.5-fold risk with more than ten years of estrogen 
use without progestin (Grady et al 1995). Combined estrogen and progestin therapy 
reduces endometrial hyperstimulation and has been found to reduce the rate of 
atypical endometrial lesions significantly; cyclic progestin therapy seems to be as 
effective as continuous low-dose progestin (Humphries and Gill 2003).  
Recently, estrogen use has been associated with a reduced risk of colon 
cancer, although the mechanisms remain unclear.  A pooled analysis of observational 
studies showed a 30 % reduction in the incidence of colon carcinoma and colorectal 
polyps among current HT users. The results of RCTs are inconsistent. The HERS II 
trial showed a nonsignificant protective effect of estrogen use (RR 0.81, 95 % Cl 
0.46-1.45). The WHI demonstrated no significant difference in rates of colorectal 
cancer (HR 1.08, CI 0.75-1.55) or total cancer among users of estrogen vs placebo 
(HR 0.93, CI 0.81-1.07) (The Women's Health Initiative Steering, Committee 2004), 
but the combination of estrogen plus progestin decreased the risk of colorectal cancer 
(HR 0.63, CI 0.43-0.92) and total cancer (HR 0.76, CI 0.69-0.85) (Rossouw et al 
2002). 
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Recent studies have revealed conflicting results concerning ovarian cancer 
risk, with no change (Sit et al 2002), or a tendency towards an increased risk among 
ever users of HT compared with never users, with the risk increasing further with 
long-term use after ten years (from 1.2-1.6 to 1.8-2.2) (Riman et al 2004). In a 
randomized comparative trial, HR associated with invasive ovarian cancer in 
connection with continuous combined HT (0.625mg conjugated equine estrogen 
(CEE) plus MPA) was 1.58 (95 % CI 0.77-3.24) (Anderson et al 2004). There is less 
information about the effects of estrogen and progestin components of HT separately 
on ovarian cancer risk, but continuous combined HT in short-term use may not be 
detrimental (Riman et al 2004). The mechanisms, by which HT increases the risk of 
ovarian cancer, remains obscure (Riman et al 2004).
 
3.7. Effects in early vs. late postmenopausal women 
Older women differ from younger women in their reasons for starting and stopping 
HT. While osteoporosis has been the predominant reason for older women to begin 
HT, the relief of vasomotor symptoms is the major reason for younger women. 
However, 10-15% of 70-year-old women suffer from vasomotor symptoms. Early 
discontinuation of HT (62 %) is common and more frequent among older (more than 
65 years) than younger (50-55 years) women. Intolerance to treatment, particularly 
vaginal bleedings and breast tenderness, is the predominant reason for stopping HT 
(Ettinger et al 1999). 
At the first few postmenopausal years bone turnover rate increases and then 
goes down before increasing again in late senescence (Mazess 1982, Garnero et al 
1994). Low estradiol levels are correlated to decreased cortical and trabecular BMD in 
late postmenopause (Khosla et al 2005). It was demonstrated recently that the lower 
the endogenous estradiol level, the higher is the response of BMD to HT in elderly 
women (Rapuri et al 2004). In women over 65 years of age, continuous combined 
low-dose estrogen (1 mg E2V) (Heikkinen et al 2000) or 0.3 mg CEE per day (Recker 
et al 1999) with MPA for 4 years resulted in mean BMD increases of  6.2% and 3.5 % 
at the spine, and 2.9% and 0.3 % at the femoral neck, respectively (Heikkinen et al 
2000). These treatments were well tolerated by most of the women. 
 Even an ultra-low-dose of 0.25 mg of oral 17β-estradiol per day significantly 
increased BMD in elderly women (>65 years old) at the hip (+2.6%), the spine 
(+2.8%), and in the total body (+1.2%), and reduced bone turnover, with minimal 
adverse effects (Prestwood et al 2003). In postmenopausal women (mean age 53 
years) transdermal E2 at doses of 0.025, 0.05, 0.06, and 0.1 mg/day increased lumbar 
spine BMD by 2.37%, 4.09%, 3.28%, and 4.70%, respectively, and total hip BMD by 
0.26%, 2.85%, 3.05%, and 2.03%, respectively. The increase of BMD may be 
dependent on the dose of estrogen and the addition of progestin (Weiss et al 1999, 
 29
Greenwald et al 2005). The effect of ultra-low-dose estrogen on BMD is seen in early 
and late postmenopausal women, but they have not been compared in the same study. 
In early menopause the intensity of symptoms usually determines the dose of 
estrogen. There are still no data on the effects of low-dose estrogen on fracture risk. 
Less than 1 % of the US noninstitutionalized population under 45 years of age 
is edentulous, but this proportion increases to 40 % for those of 65 years and older. 
The proportion of women with edentia decreases with increasing duration of HT and 
denture wearing is also less common in estrogen users vs. non-users (Paganini-Hill 
1995, Grodstein et al 1998).  
HT relieves menopausal symptoms (McNagny 1999, MacLennan et al 2001) 
and improves the general well-being of early postmenopausal women (Wiklund et al 
1992, Daly et al 1993, Zethraeus et al 1997, Genazzani et al 2002, Sintonen et al 
2003). In elderly women HT seems to have mixed effects. In the WHI study  (mean 
age of the women 63 years) HT was associated with a statistically significant, but not 
clinically meaningful QoL benefit. HT decreased pain and sleep disturbances, and 
improved physical functioning (RAND 36) (Hays et al 2003). In the HERS study 
(mean age of the women 67 years) HT seemed to have only a limited effect on 
HRQoL in women without vasomotor symptoms. However, women with vasomotor 
symptoms had less depression and improved in emotional measures with HT (Hlatky 
et al 2002). 
In the HERS study the risk of VTEs was increased by a factor of 2.7 among 
elderly women assigned to receive estrogen-progestin therapy (Manson and Martin 
2001), which is similar to the risk of VTEs in meta-analysis of 12 studies (RR 2.14, 
CI 1.64-2.81 overall, and RR 3.49, CI 2.33-5.59 during the first year) (Nelson et al 
2002). In the WHI with CEE and MPA the risk of venous thrombosis was 3.5 per 
1000 person-years for women taking estrogen plus progestin and 1.7 per 1000 person-
years for women taking placebo (RR 2.06; 95% CI, 1.57-2.70). Compared with 
women on placebo and aged 50 to 59 years, the risk ratio of VTE when on HT 
increased with age. The RR was 4.28 (95% CI, 2.38-7.72) for women aged 60 to 69 





4.1. General principles 
Bisphosphonates are synthetic analogs of the naturally occurring pyrophosphate. They 
are widely used in the treatment of osteoporosis, malignant hypercalcemia, myeloma 
and bone metastases. Bisphosphonates can be divided into two groups with different 
molecular structure and mechanisms of action.  
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The nitrogen-containing bisphosphonates (alendronate, pamidronate, 
risedronate, zoledronate and ibandronate) inhibit osteoclast-mediated bone resorption 
through the inhibition of farnesyl diphosphate synthase in the mevalonate pathway 
(Fisher et al 2000). This results in impaired protein prenylation and may affect the 
function of small GTPases in osteoclasts. These proteins are important regulators of 
vesicle transport in cells. Alendronate inactivates osteoclasts by mechanisms that 
impair their intracellular vesicle transport resulting in the accumulation of 
unprenylated, non-functional proteins, and in consequent apoptosis (Manolagas 2000, 
Alakangas et al 2002). 
Pyrophosphate-resembling bisphosphonates (clodronate and etidronate) are 
metabolized in cells into ATP-like analogs, which mediate cellular effects, such as the 
induction of apoptosis.  
Adverse effects of bisphosphonates are gastritis, esophagitis and gastric ulcers, 
but these occur in less than 1 % of patients (Devogelaer 1998, Stevenson et al 2005). 
 
4.2. Effects on bone 
In bone tissue bisphosphonates inhibit osteoclasts and prevent the apoptosis of 
osteocytes. 
Alendronate reduces postmenopausal bone loss (Hosking et al 1998, Cranney 
et al 2002), and significantly improves lumbar spine and hip BMD in osteoporotic 
women (Liberman et al 1995, Black et al 1996, Pols et al 1999, Tonino et al 2000, 
Cranney et al 2002). In postmenopausal women with a previous vertebral fracture 
(age 55-81 years) alendronate approximately halved the risk of vertebral and forearm 
fractures, and also that of hip fracture (Liberman et al 1995, Black et al 1996, Karpf 
et al 1997, Black et al 2000, Cranney et al 2002).  
Alendronate does not impair bone mineralization at the doses that maximally 
inhibit bone resorption (Rodan et al 1993). It is equally effective and well tolerated in 
osteoporotic women aged more or less than 70 years. The response in BMD is dose-
dependent, with even at daily dose of 5.0 mg producing favorable effects (Bone et al 
1997). 
 
4.3. Effects on cardiovascular risks and surrogate markers 
Bisphosphonates accumulate in artery walls and cause vasodilatation, and 
theoretically they may reduce the risk of CVD (Ylitalo et al 1998). They also cause an 
acute phase response and increase TNF-α, IL-6 (Thiebaud et al 1997) and Lp(a) levels 
and may cause a febrile reaction, when administereed intravenously (Lippi et al  
1998). Bisphosphonates affect the cells of the immune system. The nitrogen-
containing bisphosphonates are considered pro-inflammatory, but pyrophosphate-
resembling bisphosphonates are considered to be anti-inflammatory and have shown a 
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promising anti-atherosclerotic potential (Hewitt et al 2005). However, there is no 
clinical evidence of the effects of bisphosphonates on the cardiovascular events. 
 
4.4. Effects on oral health 
Bisphosphonates can inhibit the catalytic activity of MMPs in vitro, and this might be 
one potential mechanism behind the down-regulation of bone resorption (Teronen et 
al 1999). MMPs represent the family of tissue-degradative host proteinases, and they 
are involved not only in pathologic tissue destruction but also in tissue remodelling 
associated with tooth development and wound healing (Birkedal-Hansen 1993, Salo et 
al 1994, Pirilä et al 2001). 
Bisphosphonates might also have a role in adjunct therapy for periodontal 
disease (Jeffcoat 1998, El-Shinnawi and El-Tantawy 2003, Rocha et al 2004). For this 
purpose the ability of bisphosphonates to act as MMP inhibitors could be useful 
(Golub et al 1997). Bisphosphonate treatment improves the clinical outcome of non-
surgical periodontal therapy of chronic periodontitis (Lane et al 2005) and may also 
result in the promotion of bone formation around endosseous implants (Tenenbaum et 
al 2002). The decreased salivary flow rate in the menopausal period has been shown 
to increase (p=0.03) after combination treatment of HT with alendronate and calcium 
in osteoporotic women (mean age 50.7 years) (Yalcin et al 2005).  
Injectable regimens of bisphosphonates, pamidronate and zoledronate, may 
cause osteonecrosis of the jaws, which is mostly observed in patients treated for 
malignant diseases, but 7 of 63 cases were associated with oral bisphosphonates 
(Hellstein and Marek 2004, Hellstein and Marek 2005).  
 
4.5. Effects on quality of life 
Bisphosphonates are bone-tissue specific, with very few side effects and no risk of 
carcinogenesis. Women with severe osteoporosis respond to bisphosphonates with 
increasing BMD, with the future fracture risk being reduced by 40-50%. This results 
in decreased pain, and better mobilization, social well-being and QoL (Devogelaer 
1998, Dursun et al 2001). The risk of hospitalization, morbidity and mortality 




5. The combination of hormone therapy and bisphosphonates 
Women with severe osteoporosis and those who have failed to respond optimally to 
estrogen or bisphosphonate alone might benefit when they combine these two 
antiresorptive agents, with different mechanisms of action. However, previous studies 
have given conflicting results concerning whether the combination produces a net 
gain in BMD over either drug alone (Wimalawansa 1995, Wimalawansa 1998, 
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Lindsay et al 1999, Bone et al 2000, Tiras et al 2000, Palomba et al 2002, Greenspan 
et al 2003). There are no data on fracture risk concerning combination therapy with 
estrogen and bisphosphonates. Combination therapy with estrogen and 
bisphosphonate has been studied mostly in early postmenopausal women (Table 2). 
 
 
6. Calcium and vitamin D 
Inadequate dietary intake of calcium and vitamin D may contribute to the high 
prevalence of osteoporosis among older persons. Deficiency of vitamin D may lead to 
secondary hyperparathyroidism, and alone or combined with the deficiency of 
calcium, may increase bone loss in elderly women (Chapuy et al 1992, Ooms et al 
1995, Dawson-Hughes et al 1997). Vitamin D supplementation has been 
recommended especially for elderly and institutionalized people, but the net gain in 
BMD after supplementation has been moderate (1-2%) at the femur (Chapuy et al 
1992, Ooms et al 1995) and spine (Dawson-Hughes 1997). In treatment of 
postmenopausal women aged more than 60 years, an additive effect was found when 
low-dose hormone therapy (0.31mg CEE and 2.5mg MPA) was combined with a 1µg 
daily dose of 1alpha-OH-vitamin D3 (alphacalcidol) with the lumbar spine BMD 
increasing by 8.75 % vs. 2.32% on HT alone in 2 years (Mizunuma et al 2006). 
Vitamin D supplementation decreases vertebral fractures (RR 0.63, 95% CI 
0.45-0.88) and tends to decrease non-vertebral fractures (RR 0.77, 95% CI 0.57-1.04) 
(Papadimitropoulos et al 2002). A daily dose of 700 to 800 IU of vitamin D has been 
shown to reduce the risk of hip fractures by 26 % and also to decrease fall injuries, 
whereas a dose of 400 IU daily has been inefficient in the prevention of fractures 
(Bischoff-Ferrari et al 2003, Bischoff-Ferrari et al 2005). 
Calcium supplementation alone has a small positive effect on BMD and a non-
significant reductive effect on the incidence of vertebral fractures (Shea et al 2002). It 
has been shown to prevent new vertebral fractures in calcium-deficient osteoporotic 
women with earlier vertebral fractures, but not in those without previous fractures 
(Recker et al 1996).
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Table 2. Combination treatments of hormone therapy and bisphosphonates 
L: lumbar, F: Femur, Fn: Femur neck, Ttr: trochanter, Rad: Radius, Al: alendronate, CEE: conjugated estrogen, E2: estradiol, P: progesterone 
Study  N Duratio Dosage
months 
Population Age 
Study design mean 




Wimalawansa et al  
1995 
58  48 2.5g 17β-E2 transderm +200mgP + 
400mg etidonate (1) 
vs 2.5g 17β-E2 transderm                      
+200mg P (2) 
vs 400mg etidronate 14d (3)   
 vs Ca (4) 
 
Postmenopausal 
+ 1000mg Ca 
normal BMD 
 
52.6 L: 10.9 % (1) 
Vs 6.8 % (2) 
vs  6.8 % (3) 
vs -3.8 % (4) 
F: 7.3 %   (1) 
vs  4.0  % (2) 
vs  1.2 %  (3) 
vs -5.0 % (4) 




1 vs. 2,3,4 
Lindsay et al  
1999 
428  12 HT +MPA ongoing 





62 L: 3.6 %  (1) 
 vs 1%,   (2)  
Ftr:2.7%  (1) 
vs  0.5%,(2) 
Fn:1.7% (1)  
vs 0.8 (2) 
1 vs. 2 
 
1 vs. 2 
 
Bone et al  
2000 
425  24 0.625mg CEE+10mg  Al  (1) 
vs 0.625mg CEE (2) 





62 L: 8.3%  (1) 
vs 6.0% (2)  
vs 6.0%(3) 
F: 4.7%  (1) 
vs 3.4 % (2) 
vs 4.0 % (3) 
1 vs. 2,3 
 
1 vs. 2,3 
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Tiras et al  
2000 
120  12 2mg E2+1mg NETA+10mg Al (1) 
vs 2mg E2+1mg NETA (2) 




52 L: 8.4 %  (1) 
vs 2.6 % (2)   
vs 7.2  %  (3) 
Fn: 4.6 %  (1) 
vs 3.2 %  (2)  
vs 3.0%  (3)   
 
Harris et al  
2001 
542  12 0.625mg CEE+5mg MPA + 5mg 
risedronate (1) 
vs 
0.625mg CEE +5mg MPA  (2) 
Postmenopausal 
+1000mg Ca 
(+500 IU D) 
normal BMD or 
osteopenia 
 
58 L: 5.2 %    (1) 
vs 4.6 %    (2) 
Fn: 2.7 %  (1) 
vs 1.8 %    (2) 
Ftr: 3.7 % (1) 
vs 3.2 %    (2)  
Rad: 0.7  %  (1) 
vs 0.4 %    (2) 
 
 




1 vs. 2 
Palomba et al  
2002 
150  24 2mg E2+ 10mg  Al (1) 
vs 2mg E2+ 5mg Al   (2)  




60-62 L: 8%  (1)   
vs 8%   (2) 
 vs 4%  (3)   
F: 6%  (1)  
vs 6 % (2) 
vs 2%  (3)   
1,2 vs. 3 
 
1,2 vs. 3 
Greenspan et al 
2003 
373  36 0.625mg CEE+5mg MPA +10mg Al  (1) 
vs  
0.625mg CEE + 5mg MPA  (2) 




+400-800 IU D 
71 
 
L: 10.4 %  (1) 
vs 7.1 %    (2) 
vs 7.7 %    (3) 
F: 5.9 %  (1) 
vs 3.0 %  (2) 
vs 4.2 %  (3) 
1 vs. 2,3 
 
 
1 vs. 2,3 
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Aims of the study 
 
The main purpose of the present study was to explore the effects of hormone therapy 
in elderly women between 65 and 80 years of age. Two cohorts of women were 
studied 
 
I. In a cohort of women with osteoporosis, HT was compared with alendronate with 
respect to their effects on 
 
1. Bone mineral density and markers of bone turnover 
 
2. Surrogate markers of cardiovascular diseases, C-reactive protein and E-
selectin  
 
3. Oral health parameters, with special emphasis on periodontal disease, 
symptoms, saliva, and gingival crevicular fluid matrix metalloproteinase-8 
levels  
 
II. In a population-based cohort the effect of hormone therapy on health-related 




Subjects and Methods 
1. Subjects 
 
1.1. The cohort of postmenopausal women with osteoporosis (Studies I-III) 
We enrolled 90 postmenopausal women, 65–80 (mean 71) years of age, into 
this double-blind, randomized, 2-year study. Inclusion criteria were BMD at the 
lumbar spine (n=50) or femoral neck (n=71) at least 2.5 SD below the mean of a 
reference population of young premenopausal women. Exclusion criteria included 
metabolic bone disease other than postmenopausal osteoporosis, general 
contraindications of HT, use of bone-active agents (any previous use of 
bisphosphonates, concomitant use of oral glucocorticoids, or HT use less than 6 
months before the study), diseases that affect bone turnover, history of gastrointestinal 
mucosal disorders (erosive gastritis, gastric ulcer or esophagitis), history of a prior 
thromboembolic disease, liver or kidney disease, insulin-treated diabetes, history of 
uterine or breast cancer, or uncontrolled hypertension. Hypercholesterolemia (13 
patients, 9 using statins), cardiovascular diseases (23 patients), hypothyroidism 
requiring thyroxine treatment, with thyroid stimulating hormone levels within the 
normal range (11), and asthma (11) were not reasons for exclusion from the trial. The 
women were randomized to one of three treatment regimens: continuous combined 
HT (2 mg estradiol plus 1 mg norethisterone acetate (NETA) orally; Kliogest®; Novo 
Nordisk, Copenhagen, Denmark, n=30), alendronate (10 mg Fosamax®; Merck & Co. 
inc., NJ, USA, n=30), or HT plus alendronate (n=30). The baseline characteristics of 
the study population according to subsequent treatment are described in Table 3. 
Out of these 90, a subgroup of 60 women (20 in the HT group, 18 in the 
alendronate group, 22 in the combination group) were willing to participate in a dental 
examination (Study III), but only 40 subjects (44%) came to the dental examination 
two years later. The main reason for refusal was lack of interest. The drop-outs were 
evenly distributed among the study groups. In the loss analysis the only difference 
was found to be the worse subjective feeling of general health in the drop-out group, 
but no other differenceses in health parameters existed between the groups. Exclusion 
criteria for MMP-8 sampling were gingival bleeding or an edentulous state. 
The Ethics Committee of the Department of Obstetrics and Gynecology, 
Helsinki University Central Hospital, approved the study protocol and all subjects 




1.2 The population-based cohort of elderly postmenopausal women (Study IV) 
The subjects were participants in an ongoing intervention study, which is 
aimed at elucidating the effectiveness of an educational program in the prevention of 
osteoporosis and fractures. A random sample of the female population in Southern 
Finland (Uusimaa region) within the age group of 60-70 years was drawn from the 
population registry, which covers all subjects living in Finland.  In all 4200 women 
were invited to take part in the trial; 2181 (52 %) accepted the invitation and were 
recruited between 1996 and 2000. They were randomized either to the educational 
program or to the control group. 
In 2002 all 2181 participants were invited by letter to take part in the present 
study designed to illuminate health-related quality of life in the postmenopausal 
period. The participants were asked to fill in a quality of life questionnaire and to 
answer to additional questions. Overall, 1663 women (76 %; 835 participants in the 
educational program, 828 controls) aged 65-80 years completed the questionnaire; 
585 were HT users (mean age of 67.5 years) and 1078 were non-users (mean age of 
68.9 years).  
The Ethics Committee of the Department of Medicine, Helsinki University 
Central Hospital approved the study protocol and all subjects gave written informed 






















Table 3.Characteristics [mean (SD) or n (%) or medians (range)] of the study 
population (n=90). 
 
 Alendronate n=30 HT n=30 Combination n=30 p 
Age (yr) 70 (68–74) 70 (69–73) 72.5 (68–74) 0.45 
History of hysterectomy 10 (33%) 10 (33%) 10 (33%)  
Years since 
Menopause 
22.6 (6.5) 21.8 (4.9) 23 (4.7) 0.69 
Smokers (n) 5 1 5 0.19 
Dietary calcium (mg/d) 817 (434) 707 (321) 687 (287) 0.16 
Alcohol (doses/w) 0.7 (1.3) 1.2 (2.7) 1.7 (3.1) 0.21 
Height (cm) 158.8 (5.2) 158.2 (5.8) 160.7 (4.4) 0.15 
Weight (kg) 63.5 (55.0–70.3)  65.0 (59.8–70.3) 61.5 (54.8–74) 0.94 
BMI 25 (22–27)  25 (24–28) 23 (22–28) 0.45 
BPsyst (mmHg) 
 
150 (140–166) 151 (138–171) 150 (140–163) 0.74 
BPdiast (mmHg)        90 (79–95) 90 (84–97) 90 (80–97) 0.27 
BMD Lumbar spine (g/cm2) 0.740 (0.689–0.802) 0.741 (0.697–0.860) 0.771 (0.722–0.833) 0.44 
BMD Femoral neck (g/cm2) 0.609 (0.555–0.649)  0.624 (0.603–0.651) 0.614 (0.563–0.655)        0.51 
BMD Trochanter (g/cm2) 0.541 (0.088) 0.579 (0.073) 0.565 (0.084) 0.21 
BMD Total Hip (g/cm2) 0.733 (0.113) 0.778 (0.085) 0.746 (0.084) 0.13 
Urinary NTX (nmol/mmol 
Crea) 
71.5 (51.7–89.7) 66.9 (48.2–90.6) 67.1 (52.1–83.7) 0.92 
Serum PINP (µg/l) 49.5 (38.8–66.8) 50.0 (34.5–58.8) 47.0 (36.8–59.3) 0.76 
Serum 25(OH)D (nmol/l) 46.0 (37.8–66.0) 
 
52.0 (38.8–65.0) 54.5 (28.0–66.3) 0.97 
CRP (mg/l) 
 
1.7 (1.4) 1.4 (1.2) 1.4 (1.8) 0.93 
E-Selectin (µg/l) 42.6 (17.1) 47.4 (17.1) 46.3 (16.8) 0.11 












Table 4. Characteristics [mean (SD) or n (%)] of the population-based cohort 













Age, years 68.9  (3.4) 67.5  (3.1) <0.0001 
Flushing 
 All of the time 
 Most of the time 
 Some of the time 
 Little of the time 
 None of the time 
 
 
 8     (1.0) 
18    (2.0) 
52    (5.0) 
174  (16) 




1      (0.2) 
6      (1.0) 
17    (3.0) 
62   (10.8) 




Number of chronic diseases 
 0 
 1-3 
 4 or more 
 
257   (26) 
688   (70) 
41      (4) 
 
172    (32) 
350    (64) 
23      (4) 
 
0.068 
Number of medication 
 0 
 1-2 
 3 or more 
 
 
226   (23) 
347   (35) 
417   (42) 
 
139   (25) 
223   (41) 
188   (34) 
 
0.009 
Number of antidepressant 
users 
 Never 
 More than 5 years ago 
 Now or during 5 years 




885  (89.5) 
32    (3.4) 
63    (7.1) 
 
481 (87) 
19    (3) 





 Primary school 
 Comprehensive school 
 High school 
 
 
485   (51) 
298   (32) 
160   (17) 
 
 
193   (36) 
173   (33) 







 Vocational courses 




147  (17) 
345  (40) 
124  (14) 
155  (18) 
101  (11) 
 
59     (12) 
173   (34) 
65     (13) 
109   (21) 






2. Study protocols:  
 
2.1. Effect of hormone therapy, alendronate, and their combination on bone 
mass and turnover (Study I) 
The women were randomized (using an outside computer program) to one of 
three treatment regimens: continuous combined HT (2 mg estradiol plus 1 mg NETA 
orally; Kliogest®; Novo Nordisk, Copenhagen, Denmark, n=30), alendronate (10 mg 
Fosamax®; Merck & Co. Inc., NJ, USA, n=30), or HT plus alendronate (n=30). The 
principle of double dummy techniques was followed so that each regimen was similar 
in appearance. The women were instructed to take alendronate or its placebo in the 
morning, at least 30 min before the first meal of the day, with a glass of water, and to 
remain upright for at least 30 min after dosing. HT or its placebo was taken in the 
evening. At baseline, dietary calcium intake was assessed by using a questionnaire. In 
addition to the study medication, the participants were instructed to take calcium 
supplementation (500–1000 mg/day) and vitamin D (400 IU/day) during the fall and 
winter months from October to April, but we did not provide them. Compliance in use 
of the study medication was assessed by counting the unused tablets. The subjects 
were seen at baseline and at 6, 12, 18 and 24 months. At each visit, a clinical and a 
pelvic examination were performed. The BMD of the lumbar spine and hip (femoral 
neck, trochanter and total hip) was measured at baseline and at 12 and 24 months 
using the same densitometer over the whole duration of the study. Serum and second 
void urine samples were obtained in the morning after an overnight fast at baseline 
and at 6, 12, 18 and 24 months for assay of biochemical markers of bone turnover, 
and serum 25-hydroxyvitamin D (S-25(OH)D). The samples were stored at –28 ºC 
until assayed. 
 
2.2. Effect of hormone therapy, alendronate, and their combination on surrogate 
markers of cardiovascular diseases (Study II) 
This study was performed in the same study population as in Study I by 
collecting blood samples for the determination of serum CRP, E-selectin, and SHBG 










2.3. Effect of hormone therapy, alendronate, and their combination on oral 
health (Study III) 
 Dental, periodontal and intra- and extraoral status was recorded at the beginning 
and at the end of the study at 24 months. For the saliva and gingival crevicular fluid 
(GCF) tests the subjects were instructed not to eat or smoke for two hours prior to the 
examination. Panoramic tomography of the jaws (OPTG) was carried out before the 
clinical examinations. A structured questionnaire was given to all the subjects prior to 
the examinations. The questionnaire comprised multiple-choice questions on smoking, 
self-assessed general and dental health, and an enquiry regarding the last visit to a 
dentist. Subjective concepts of periodontal health of the women were investigated by 
means of multiple-choice questions on gingival bleeding during tooth brushing. Resting 
and stimulated flow rates of saliva were measured. Resting saliva was collected by 
means of the free flowing method for 3 minutes (Meurman and Rantonen1994, 
Närhi1994). To stimulate saliva secretion a 1-gram piece of paraffin wax was given to 
the women for them to chew. The collection time for stimulated saliva was also 3 min. 
All the dental examinations were carried out by the same examiner (L.T.). Samples of 
GCF for assay of MMP-8 levels were collected from periodontal pockets of two teeth 
of each subject (n=34). Exclusion criteria for MMP-8 sampling were gingival bleeding 
or an edentulous state (11 were excluded). Before taking the sample for MMP-8 
measurement supra-gingival plaques were removed and the sampling sites were isolated 
with cotton rolls and dried gently to avoid saliva contamination. The samples of GCF 
were taken with a filter-paper sampling strip. The strip was placed into the gingival 
crevice for 30 seconds. It was then placed in a test tube and frozen at -20°C until 
analysed (Sorsa et al 1999, Mäntylä et al 2003). 
 
2.4. Effect of hormone therapy on health-related quality of life in the population-
based cohort of elderly postmenopausal women (Study IV) 
The participants were asked to fill in a quality of life questionnaire (generic 15 D) and 
to answer additional questions.  All participants were asked if they currently used HT. 
Flushing symptoms were enquired about by the question “During the last week, did 
hot flushes bother you?”, and information was classified as “all of the time”, “most of 
the time”, “some of the time”, “a little” and “none of the time”. We also obtained 
information on basic education (primary, comprehensive or high school), professional 
education (none, vocational courses, vocational school, college or university), the 
number of ongoing chronic diseases, and continuous medication. Medication for 







3.1. Bone mineral density 
The BMD of the lumbar spine (L1-4) and hip (femoral neck, trochanter and total hip) 
was measured at baseline and at 12 and 24 months by dual-energy X-ray 
absorptiometry (DXA) (Hologic, Inc., QDR 1000W, Waltham, MA, USA), using the 
same densitometer over the whole duration of the study. Data were given as areal 
density (g/cm²). The coefficient of variation (CVs) of the spine and femoral neck 
measurements were 0.9 % and 1.2 %, respectively. 
Primarily the BMD of L1-4 was used for the analyses, but in cases of severe 
changes (arthrosis, fracture, scoliosis, etc) L1-3, L1-2, L2-3 or L 3-4 were used 
instead. In follow-up, the BMD of the same vertebrae was always analyzed. 
 
3.2. Bone turnover markers and serum 25(OH)D 
The urinary N-telopeptide (NTX) of type I collagen as related to creatinine was 
measured as a marker of bone resorption, using an ELISA (Osteomark NTx Test, 
Ostex International, Seattle, WA, USA). The intra-assay CV was 8 % and the 
interassay CV 13 %. The serum aminoterminal propeptide of human type I 
procollagen (PINP) was measured as a marker of bone formation, using RIA kits 
(Orion Diagnostica, Espoo, Finland). The intra- and interassay CVs were 7 %. Serum 
25(OH)D was measured by RIA (Immunodiagnostic Systems Ltd (IDS), Boldon, 
UK). The intra- and interassay CVs were 6 %. 
 
3.3. C-reactive protein, E-selectin, and sex hormone binding globulin  
CRP was measured immunochemically using of monoclonal antibodies produced in 
mice (DADE-Behring Marburg GmbH, Marburg, Germany). The intra- and inter-
assay CVs were 2 % and 3 %. Because CRP concentrations rise in acute infections, 
seven subjects with CRP values exceeding 10 mg/L were excluded.  
E-selectin was measured by a sandwich enzyme immunoassay (R&D Systems, 
Minneapolis, MN). The intra-assay variation CV was below 5 %, and the interassay 
CV below 9 %.  
SHBG was measured with a solid phase, two-site fluoroimmunometric assay 
(DELFIA®, Wallac Oy, Turku, Finland). The intra-assay CV was less than 2 %, and 
the interassay CV 5 %. 
 
3.4. Oral health measurements and matrix metalloproteinase-8 
3.4.1. Clinical dental recordings and questionnaire 
Dental status was recorded using WHO criteria (Anonymous 1987). Because not all 
women remembered their history of dental treatment, especially reasons for tooth 
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extractions, the third molars were included in recording the numbers of decayed teeth 
(DT), filled teeth (FT) and the total number of teeth. However, in calculating the 
WHO DMFT-index the third molars were not included (M=missing teeth). A review 
of OPTG X-ray films by a radiologist specialized in oral disease, was available at the 
clinical examination. The number of incidences of periapical radiolucency, 
endodontically treated teeth, and furcation lesions of multi-rooted teeth were counted 
from the X-ray films.  
3.4.2. Periodontal health status  
Periodontal health status and need of treatment were recorded using the WHO 
Community Index of Periodontal Treatment Need (CPI) (Ainamo et al 1982). All 
surfaces of the teeth were examined. The mouth sextants were scored on the basis of 
the worst finding in the respective sextant. Periodontal probing depths were measured 
to the nearest mm from the gingival margin to the bottom of the periodontal pocket at 
four surfaces of each tooth with a WHO periodontal ball-point probe (tip diameter 0.5 
mm).  
3.4.3. Buffering capacity  
Buffering capacity was assessed immediately after collecting saliva using the 
Dentobuff Strip® method (Orion Diagnostica Ltd., Espoo, Finland). Score 1 
corresponds to buffering end-pH > 6, score 2 to pH 4.5-5.5 and score 3 to end-pH less 
than 4.5. A pH value < 4.5 (score 3) was recorded as a low buffering capacity (Närhi 
et al 1993).  
3.4.4. Oral yeasts 
To assess the prevalence of yeasts, the Dentocult CA® dip slide method (Orion 
Diagnostica Ltd, Espoo, Finland) was used. Score 1 corresponds to 0 to 20 colony-
forming units (CFU) per ml, score 2 corresponds 21-50 CFU/ml, and score 3 to more 
than 50 CFU/ml.  
3.4.5. Salivary total protein and albumin 
The salivary concentrations of protein and albumin were determined by colorimetric 
analyses. Salivary immunoglobulin concentrations (IgG, IgM, IgA) were analyzed by 
means of enzyme immunoassays. 
3.4.6. Resting and stimulated flow rates of saliva  
Resting flow rates of saliva below 0.1 ml/min and stimulated flow rates below 0.7 
ml/min were regarded as reduced salivary flow rates (Meurman and Rantonen 1994, 
Närhi 1994).  
3.4.7. Matrix metalloproteinase-8 
Levels of MMP-8 in the GCF samples were determined by a time-resolved 
immunofluoresence assay (IFMA). Fluorescence was measured using a 1234 Delfia 
Research Fluorometer (Wallac, Turku, Finland)(Hanemaaijer et al 1997, Liede et al 
1999, Sorsa et al 1999). Specific monoclonal antibodies 8708 and 8706 to MMP-8 
were used as catching and tracer antibodies, and the tracer antibody was labelled 
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using europium-chelate. The specificities of the monoclonal antibodies against MMP-
8 corresponded to those of polyclonal MMP-8 antibodies and they did not detect other 
MMPs (Lauhio et al 1994, Hanemaaijer et al 1997, Liede et al 1999, Sorsa et al 
1999). The results were reported as total MMP-8 (µg/ml) in the sample. 
 
3.5. Health-related quality of life questionnaire (15D) 
Health-related quality of life  measurement 
The 15D questionnaire is a generic, comprehensive, 15-dimensional, 
standardized, self-administered questionnaire giving a measure of HRQoL that can be 
used both as a profile and single index score measure. The dimensions are: mobility, 
vision, hearing, breathing, sleeping, eating, speech, elimination, usual activities, 
mental function, discomfort and symptoms, depression, distress, vitality and sexual 
activity. Each dimension is divided into five ordinal levels, by means of which more 
or less of the attribute can be distinguished. The person ticks, for each dimension, the 
level that best describes his or her health status. The single index (15D score) on a 0-1 
scale, representing the overall HRQoL, is calculated from the health state descriptive 
system by using a set of population-based preference or utility weights. Such a weight 
for each level of each dimension is obtained by multiplying the level value by the 
importance weight of the dimension at that level. The level values on a 0-1 scale, 
reflecting the goodness of the levels relative to no problems on the dimension (=1) 
and to being dead (=0), and the importance weights summing up to unity, have been 
elicited earlier from representative population samples. A difference of > |0.03| in the 
overall 15D score is clinically important in the sense that on average people can feel 
the difference (Sintonen1994, Stavem 1999, Hawthorne et al 2001, Sintonen 2001, 
Sintonen et al 2003). 
 
 
4. Statistical analyses 
 
In Study I data with normal distributions are expressed as means with SDs; otherwise 
as medians with interquartile ranges (IQRs). In comparisons between the study 
groups, normally distributed variables were studied using one-way ANOVA followed 
by Bonferroni correction in paired comparisons. Those data non-normally distributed 
were tested by means of Kruskal-Wallis one-way ANOVA on ranks. Bone mineral 
density changes were analyzed by repeated measures repeated measures (RM) 
ANOVA or by using percentage changes from 0 to 12- and 24-month time points. 
Because the assumptions for repeated measures ANOVA were not fulfilled for the 
biochemical results, a summary variable “area under the curve” (AUC) was calculated 
and analyzed by ANOVA in the analysis of differences between the groups. 
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Additionally, Friedman RM ANOVA was used in the analysis of changes within a 
single study group. The analyses were carried out using NCSS 2000 software (NCSS 
Statistical Software, Kaysville, Utah, USA) or SigmaStat for Windows (Version 2.0, 
SPSS Inc., Chicago, IL, USA). 
 In Study II the SPSS 10.0 statistical package (SPSS Inc., Chicago, Illinois, 
United States) was used. The levels of the biomarkers at baseline or during the trial 
were compared with the Mann-Whitney U-test and the changes during the trial with 
the Sign test. 
 In Study III all the results were analyzed using SPSS for Windows version 
11.0 software (SPSS Inc., Chicago, Illinois, United States) to detect differences 
between and changes within the study groups. Due to the small sample sizes only 
nonparametric analyses (Kruskal-Wallis test, Chi2 test, Wilcoxon test) were used. 
Values of p < 0.05 were considered statistically significant. 
In Study IV the difference in age of HT users vs. non-users was tested by 
using independent samples t-test. Differences between the groups in categorial 
variables (flushing, number of chronic diseases and medication, basic and 
professional education) were tested with the Chi-Square test. 
Since the groups of estrogen users and non-users were not assigned randomly, 
any possible difference in the 15D score between the groups may be due to 
differences in important background and clinical characteristics between the groups. 
To account for such characteristics, the variance in the 15D score was explained by a 
Tobit regression model with age, the number of medication and chronic diseases as 
well as education as covariates in addition to a dummy indicating, whether the person 
was an estrogen user or not. The Tobit regression model is suitable for two reasons. 
The distribution of dependent variables (15D score) is not normal, but skewed and 
censored at 0 and 1 due to the fact that its range is 0-1 and the fact that a considerable 
number of observations were at the upper limit of 1 (7.5 %). The Tobit model 
accounts for these special features of the distribution.  
Tobit models with the same explanatory variables were also used to create a 
15D profile for both groups. The profiles indicate the average level value on a 0-1 
scale for each group in each dimension, when the groups were standardized for age, 
number of medication and chronic diseases as well as education. A p-value of # 0.05 
was regarded as statistically significant. The data were analyzed using Limdep 7.0 








1. Effect of hormone therapy, alendronate, and their combination on bone (Study I) 
 
1.1. Bone mineral density   
Lumbar spine BMD increased similarly in all treatment groups (p<0.0001 vs. 
baseline) (Fig. 2). The increases ranged from 6.8% to 8.4% at 12 months and from 
9.1% to 11.2% at 24 months. Only HT increased femoral neck BMD statistically 
significantly at both 12 (+4.9%; p<0.0001) and 24 months (+5.8%; p<0.0001). At the 
latter time point, the HT group differed significantly from the other groups (p<0.05). 
The alendronate group exhibited a significant increase of +3.3% from baseline at 12 
months (p<0.05), and the combination treatment group showed an increase of +2.7% 
at 24 months (p<0.05). All treatments raised trochanter BMD (p<0.001–0.0001 for 
differences from baseline at 12 months; p<0.0001 at 24 months), with the alendronate 
group showing the biggest increases both at 12 months (+5.8%; p<0.01 vs. the other 
groups) and 24 months (+8.5%; p<0.01 vs. the combination treatment group). Total 
hip BMD increased in all study groups (p<0.05–0.0001 for differences from baseline 



























































































Fig. 2. Mean (SEM) percentage changes from baseline in bone mineral density (BMD) of 
lumbar spine (A), femoral neck (B), and total hip (C). *p<0.05, **p<0.0001 for differences 
from baseline. #p<0.05 for differences vs. the other two groups. 
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1.2. Biochemical markers of bone turnover 
Significant reductions from baseline were seen in all treatment groups from 6 months 
onwards (p<0.001) in both urinary NTX and in serum PINP (Fig. 3). Percentage 
changes in urinary NTX ranged from -60.2% to -62.7% in the HT group, these being 
significantly smaller than those of -78.1% to -80.4% in the combination treatment 
group (p<0.001-0.0069). In the alendronate-only group the respective reductions 
ranged from -72.4% to -76.1%, which differed from those in the HT-only group at 24 
months (p=0.047) and those in the combination group at 12 months (p=0.002). Serum 
PINP decreased less in the HT group (-53.6% to -59.8%) than in the other groups (-
73.0% to -75.0% in the alendronate group [p<0.001 at 12 months]; -67.0% to -71.5% 






















































 Fig. 3. Mean (SEM) percentage changes from baseline in bone turnover markers, urinary 
NTX (A) and serum PINP (B). Changes from baseline were significant in all three study 
groups (p<0.001, Friedman RM ANOVA). †p<0.0001 for the difference between the HT 
group and combination groups; ‡ p=0.002 for the difference between the alendronate and 
combination groups; # p<0.001 for the difference to the other two groups; * p=0.047 for the 
difference between the HT and alendronate groups and p=0.0069 for the difference between 




1.3. Relationship between changes in bone mineral density and bone markers 
In the whole study population, the maximum reduction in serum PINP levels 
correlated with the increase in lumbar spine BMD at both 12 (r=0.34, p=0.004) and 24 
months (r=0.24, p=0.04). Respectively, the maximum drop from baseline in urinary 
NTX correlated with the increases in lumbar spine BMD at both time points (r=0.32-
0.40, p<0.001-0.007) and in total hip BMD at 24 months (r=0.27, p=0.02). However, 
as calculated from these poor correlations (r² values) the marker changes explained 
only 10-15% of BMD changes. 
1.4. Serum 25(OH)D 
Serum 25(OH)D concentrations were similar in all treatment groups at baseline and 
they remained at the same level throughout the study. Hypovitaminosis D as defined 
as a serum 25(OH)D level less than 37 nmol/L (15 ng/mL) was found in 18.9%, 




2. Effect of hormone therapy, alendronate, and their combination on surrogate 
markers of cardiovascular diseases  and serum sex hormone binding globulin (Study 
II) 
 
2.1. C-reactive protein 
In the HT group CRP concentrations were increased by a mean of 76.5% at 6 months 
(p < 0.001) and 47.1% at 12 months. Alendronate alone did not affect the levels of 
CRP and did not blunt the HT-induced rises in the HT + alendronate -group, in which 
the average rises were 50.0% at 6 months (p=0.031) and 52.9% at 12 months 
(p=0.019) (Table 5). 
2.2. E-selectin 
Concentrations of E-selectin in the HT group were decreased at 6 months by 24.3% 
(p<0.001) and at 12 months by 30.0% (p<0.001). Alendronate had no effect on E-
selectin and did not block the effect of HT in reducing E-selectin levels (Table 5). 
2.3. Sex hormone binding globulin  
In the HT group concentrations of SHBG were increased at 6 months (14.8 %; 
p<0.05) and at 12 months (11.0%; p=0.09). Alendronate, or HT plus alendronate did 
not have any effect on SHBG levels. No significant correlation between the changes 





Table 5. Levels (mean ± SD) of CRP, E-selectin, and SHBG before and during 
treatment with estrogen-progestin (HT), alendronate, or HT+alendronate. 
 
    Baseline     6months  12months  
CRP (mg/L):  
HT    1.4 (1.2)     2.4 (2.1)** 2.0 (1.6) 
 Alendronate   1.7 (1.4)     1.5 (1.7)  1.7 (2.1) 
 HT+Alendronate  1.4 (1.8)     2.0 (1.6)* 2.1 (1.6)* 
  
E-Selectin (µg/L):  
HT   47.4 (17.1)  35.9 (15.7)** 33.2 (14.6)** 
 Alendronate  42.6 (17.1)  43.8 (18.3) 40.7 (16.7) 
 HT+Alendronate  46.3 (16.8)  36.4 (15.2)** 35.9 (13.7)** 
  
SHBG (nmol/L): 
HT   78.8 (31.6) 90.5 (29.2)* 87.5 (32.0) 
 Alendronate  89.9 (27.6) 86.5 (25.0) 87.7 (33.2) 
 HT+Alendronate  106.3(32.9) 96.5 (37.9) 91.8 (29.7) 
  
*p<0.05 for  changes from baseline 





3. Effect of hormone therapy, alendronate, and their combination on oral health 
(Study III) 
 
3.1.  Dental and oral status 
No significant differences were observed in any dental or oral health status parameters 
between the groups at baseline. The number of patients with severe periodontitis 
increased (NS) in all the study groups in terms of both the CPI values and in the 
number of deep periodontal pockets. The increase in the number of deep periodontal 
pockets between baseline and follow-up recordings was significant in the HT and 








Table 6. Baseline and follow-up (24 months) oro-dental status findings [mean (SD), no (%)]. 
* p<0.05 
  HT group    
 Alendronate 
group   
Alendronate  
+ HT group    
  Baseline Follow-up Baseline Follow-up Baseline Follow-up 
       
N 20 15 18 11 22 14 
Number of teeth, 19 ± 8 17 ± 9 16 ± 9 17 ± 10 17 ± 10 17 ± 10 
Edentulous 1 (5 %) 1  (7 %) 3   (17 %) 1 (9 %) 4 (18 %) 3 (21 %) 
Prosthesis in 
upper jaw 9 (45 %) 7 (47 %) 11 (61 %) 4 (36 %) 9 (41 %) 6 (43 %) 
Prosthesis in 
lower jaw,  7 (35 %) 6 (40 %) 7 (39%) 4 (36 %) 7 (32 %) 6 (43 %) 
DMF index    23 ± 3     24 ± 4      *↑ 23 ± 3 22 ± 3 23 ± 4 23 ± 4 
DT 0.8 ± 1.3 0.7 ± 1.0 0.4 ± 0.9 0.3 ± 0.5 0.5 ± 0.9 0.7 ± 1.3 
FT 13 ± 6 13 ± 7 11 ± 7 12 ± 7 12 ± 8 11 ± 9 
Nunber of 
periodontitis 1 (5 %) 2 (14 %) 1 (7 %) 1 (11 %) 1 (6 %) - 
Mild periodontitis 9 (47 %) 3 (21 %) 4 (27 %) 1 (11 %) 3 (17 %) - 
Severe 
periodontitis 9 (47 %) 9 (64 %) 10 (67 %) 7 (78 %) 14 (78 %) 11 (100 %) 
Nunber of teeth 
with gingival 
pockets >6mm,   1.5 ± 2.0  2.1 ± 2.2   *↑ 1.6 ± 1.6 2.8 ± 2.0 1.5 ± 1.9   2.8 ± 1.9   *↑ 
Lesions of mouth 
mucosa 
 
15 (75%) 12 (80%) 12 (67%) 6 (54%) 13 (59%) 9 (64%) 
Signs of TMJ 
dysfunction 
15 (75 %) 10 (67 %) 5 (28 %) 3 (27 %) 10 (45 %) 5 (36 %) 
DMF=Diseased, missing, filled teeth 
DT=Diseased teeth 
FT=Filled teeth 
TMJ= Temporomandibular joint 
 
 
3.2. Salivary findings and matrix metalloproteinase-8 
In comparison with baseline values, the resting salivary flow rate decreased by 19.4 % 
in the alendronate group (p < 0.05). The number of women reporting subjective 
feelings of dry or burning mouth remained the same in each group, with no difference 
between the groups. The levels of GCF MMP-8 increased in one of the periodontal 
pockets sampled (A2) in the alendronate group (p < 0.05), but in the other pocket 
(A1) the increase was not significant. In the HRT and combination groups no changes 
were detected in the concentrations of GCF MMP-8. Salivary protein concentrations 
remained unchanged in all study groups.  No statistically significant changes or inter-




Table 7. Baseline and follow-up (24 months) salivary flow rates, buffering capacity, yeast 
counts and biochemical constituents [mean+SD or n(%)]. 
 
 
  HT group    
Alendronate 
group    
Alendronate 
+HT group    
  Baseline Follow-up Baseline Follow-up Baseline Follow-up 
       
N 20 15 18 11 22 14 
Resting salivary flow rate 0.54 ± 0.32 0.65 ± 0.43 0.72 ± 0.46 0.58 ± 0.31* 0.59 ± 0.36 0.70 ± 0.42 
  (ml/min)       
Stimulated salivary flow rate 1.54 ± 0.82 1.96 ± 1.06 1.83 ± 0.90 1.71 ± 0.83 1.78 ± 0.71 2.23 ± 1.12 
 (ml/min)       
High buffering capacity 14 (78 %) 8 (57 %) 16 (89 %) 8 (89 %) 19 (91 %) 10 (77 %) 
Medium buffering capacity 3 (17 %) 5 (36 %) 2 (11 %) 1 (11 %) 2 (10 %) 3 (23 %) 
Low buffering capacity 1 (6 %) 1 (7 %) - - - - 
Positive yeast count 14 (78 %) 10 (67 %) 11 (61 %) 4 (36 %) 16 (76 %) 11 (85 %) 
MMP-8 A1 (µg/ml) 299 ± 245 296 ± 286 169 ± 115 199 ± 101 212 ± 155 189 ± 189 
MMP-8 A2 (µg/ml) 262 ± 205 426 ± 525 208 ± 157 300 ± 185* 136 ± 128 242±213 
Albumin (µg/ml) 277 ± 140 262 ± 134 250 ± 143 248 ± 201 252 ± 107 247 ± 144 
Salivary total protein (mg/ml) 1.58 ± 0.33 1.55 ± 0.51 1.64 ± 0.35 1.56 ± 0.44 1.55 ± 0.36 1.40 ± 0.43 
IgA (µg/ml) 34.1 ± 15.4 28.1 ± 15.1 27.3 ± 7.0 26.5 ± 10.8 28.0 ± 15.2 27.9 ± 33.9 
IgG (µg/ml) 26.4 ± 19.3 22.2 ± 18.6 17.3 ± 16.0 13.8 ± 14.1 24.0 ± 14.1 21.7 ± 18.6 
IgM (µg/ml) 1.99 ± 1.93 1.87 ± 2.65 1.26 ± 1.00 1.18 ± 1.44 1.10 ± 0.60 0.99 ± 1.74 
*p<0.05 for within-group 





4. Effect of hormone therapy use on the health-related quality of life  in the 
population-based cohort of postmenopausal women (Study IV) 
The users of HT were younger (p<0.0001) and healthier in terms of the amount of 
concomitant medication (p= 0.009) and chronic diseases (p=0.068) and they reported 
fewer hot flushes (p<0.001). The HT users had higher basic and professional 
education than the non-users. On average, HT users were taking fewer types of 
medication than the non-users (2.1 vs. 2.4, p=0.004). The use of medication for 
depression did not differ between HT users and HT non-users (Table 4).  
 Of the explanatory variables, the number of types of medication and the 
number of concomitant chronic diseases, but not age, estrogen use or high education, 
were statistically significant in the Tobit model (Table 8). The model suggests that the 
number of types of medication and chronic illnesses have a statistically significant 
negative effect, but that high education has a positive, but non-significant effect on 
HRQoL. After standardizing for age, education, number of types of medication, and 
 52
illnesses, the marginal effect of HT use on overall HRQoL on a 0-1 scale was positive 
(=+0.0053), but statistically non-significant (p=0.21) and less than 0.03, and 
consequently, not clinically important (Table 8). Indeed, none of the marginal effects 
of the studied variables exceeded the limit of clinical importance. Without 
standardization the mean 15D scores of the users and non-users were 0.897 and 0.883, 
respectively. 
Figure 4 shows the 15D scores and profiles of the groups after standardizing 
for age, education, number of types of medication, and diseases. The hormone users 
were statistically significantly better off than non-users in the dimensions of usual 
activities (p=0.0058), vitality (p=0.0076) and sexual activity (p=0.0001), but there 







Table 8. Results of the Tobit model explaining the variance in the 15D score 
 
Variable Coefficient Marginal 
effect 
t-value p-value 
Constant 1.0044 0.9093 21.671 <0.0001 
Estrogen use (1=yes, 0=no) 0.0058 0.0053 1.241 0.21 
Number of medications -0.0140 -0.0127 -9.906 <0.0001 
Age (years) -0.0009 -0.0009 -1.404 0.16 
Number of chronic diseases -0.0144 -0.0130 -5.397 <0.0001 
High education (1=yes, 0=no) 0.0068 0.0062 1.302 0.19 
Sigma (disturbance standard 
deviation) 










Figure 4. The 15D scores and profiles of the HT users and non-users standardized for 
age, education, number of medications and chronic diseases. Differences favouring 
HT use were significant for usual activities (p=0.0058), vitality (p=0.0076), and 
sexual activity (p=0.0001) 15 dimensions:   
mobility, vision, hearing, breathing, sleeping, eating, speech, elimination, usual 
activities, mental function, discomfort and symptoms, depression, distress, vitality and 




































































1. Rationale for the study 
At the start of the present study estrogens played a major role in the treatment of 
osteoporosis. Their efficacy in the prevention of osteoporosis (The Writing Group for 
the PEPI trial 1996) and in the treatment of established osteoporosis (Lufkin et al 
1992) had been clearly demonstrated. Observational studies indicated that estrogens 
also prevent CVDs (Grodstein et al 1996) and deaths (Sourander et al 1998) and it 
was believed that they could improve the quality of life of postmenopausal women 
(Wiklund et al 1992, Daly et al 1993, Zethraeus et al 1997).  Elderly women were 
also generally treated with estrogens, a fact that was still seen in the 35 % share of 
estrogen users in our population-based cohort of elderly women in the year 2002. 
However, data on the efficacy and safety of ERT came mainly from younger 
postmenopausal women. Consequently, we focused the present study on elderly 
women.  
 During our investigation the randomized trials HERS and WHI demonstrated 
that the use of HT in healthy, asymptomatic postmenopausal women lacks overall 
health benefits and confers several health risks, with breast cancer,VTE and stroke 
being the most important ones (Hlatky et al 2002, Hays et al 2003). The increased risk 
of breast cancer was of the same magnitude as in earlier epidemiological studies 
(Anonymous 1997). It was also known that current HT use is associated with an 
increased risk of VTE (Daly et al 1996).  However, despite the fact that these new 
results from RCTs greatly reduced the use of HT,  postmenopausal women may 
consider well-being to be a more important factor than the reported health risks and 
want to start HT. On the other hand, regarding the CVD risk, timing of the start of HT 
may be very important. The latest evidence from the WHI study indicates that the risk 
of cardiovascular events is not increased if HT is started between 50 to 59 years of 
age (HR 0.63, 95% CI 0.36-1.08) (Hsia et al 2006). Furthermore, we do not have any 
data from randomized controlled trials to tell us what kind of long-term CVD risk HT 
use confers if started at the menopause and continued until the age of 70 to 80 years, 
for example.   
 Interestingly, recent observations suggest that postmenopausal women with 
osteoporosis are at an increased risk of CVD (both coronary events and stroke) that is 
proportional to the severity of osteoporosis at the time of diagnosis. Treatment of 
postmenopausal osteoporosis should therefore include consideration of measures to 
prevent undesirable cardiovascular outcomes (Tanko et al 2005), or, at least, not to 
affect health status negatively. Consequently, studies in which different treatments of 
osteoporosis (e.g. HT and bisphosphonates) are compared as regards their effects on 
surrogate markers of CVDs are important. The underlying mechanism by which these 
two major epidemiologic diseases are linked is not fully understood, but suggested 
linking factors include regulators of bone turnover, e.g. a matrix GLA protein, 
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osteocalcin, and osteoprotegerin, proinflammatory cytokines such as IL-6 and TNF-α, 
oxidized lipids, and NO synthase (Tanko et al 2005). 
 Examination and treatment of osteoporosis is most profitable when directed to 
women aged 65–70 years (Black 1995). Women with severe osteoporosis or those 
who have failed to respond optimally to estrogen or bisphosphonate alone might 
obtain additive benefit when they combine these two antiresorptive agents, with 
different mechanisms of action. Estrogen inhibits bone resorption by decreasing the 
activity of osteoclasts and by increasing their apoptosis (Manolagas 2000). Estrogen 
affects through receptors in the osteoblasts by down-regulating the expression of bone 
resorbing cytokines, such as interleukins and tumor necrosis factor-α. 
Bisphosphonates inhibit osteoclasts, and prevent the apoptosis of osteocytes, but the 
mechanisms by which bisphosphonates inhibit osteoclasts are not totally clear.  
 We compared the continuous combination of 2 mg estradiol plus 1 mg NETA 
daily with 10 mg of alendronate daily, separately and in combination for two years. 
The inclusion of a placebo group was considered unethical, since low BMD combined 
with advanced age is a straightforward indication for treatment of osteoporosis. A 
lower dose of continuous combined regimen with 1 mg of estradiol, which is now 
preferable in this age group, was not commercially available in Finland at the time of 
the start of the study  
 
2. Effects of hormone therapy , alendronate, and their combination on bone  
In the WHI study estrogens reduced the incidence of vertebral and non-vertebral, and 
also hip fractures in a population that was not selected for BMD or fracture history 
(Rossouw et al 2002, Cauley et al 2003). In a randomized placebo-controlled trial 
estrogen decreased the risk of vertebral fractures in postmenopausal women with 
established osteoporosis statistically significantly (Lufkin et al 1992). In a cohort 
study HT effectively prevented hip fractures among women older than 75 years 
(Cauley et al. 1995). Estrogens combined with progestins may increase vertebral 
BMD more than estrogens alone (Christiansen et al 1990, Speroff et al 1996, Wring 
group for the PEPI trial 1996, Torgerson et al 2001, Nelson et al 2002).  
 Alendronate is the most widely studied bisphosphonate, and it has 
approximately halved the risk of vertebral and forearm fractures, and also that of hip 
fractures (Lieberman et al 1995, Black et al 1996, Karpf et al 1997, Black et al 2000) 
in postmenopausal women with osteoporosis, of 55-81 years of age. Besides estrogens 
and alendronate, only risedronate (McClung et al 2001), and in a subgroup analysis 
also strontium ranelate (Reginster et al 2005) have significantly reduced the risk of 
hip fractures. 
 In our study of elderly osteoporotic women, two years’ combination treatment 
did not offer an extra benefit over either treatment alone in terms of changes in BMD. 
DXA was chosen as a tool to measure BMD repeatedly, because it provides good 
precision (error 1-2%) at a low radiation burden, stable calibration and a short 
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scanning time (2-5min). Lumbar spine BMD increased similarly in all treatment 
groups, ranging from 6.8 % to 8.4 % at 12 months and from 9.1 % to 11.2% at 24 
months. HT increased femoral neck BMD significantly by 4.9 % and 5.8% at 12 and 
24 months respectively. At the latter time point the increase in femoral neck BMD 
was significantly greater in the HT group than in the other groups. However, the 
increases in BMD explain only part of the reduction in vertebral fracture risk in 
response to antiresorptive treatments (4% for raloxifene, 16 % for alendronate, 28 % 
for risedronate)(Cummings et al 2002, Sarkar et al 2002, Delmas and Seeman 2004, 
Sarkar et al 2004) and none of the reduction in non-vertebral fracture risk (Delmas 
and Seeman 2004). 
 Markers of bone metabolism are sensitive tools when following the effect of 
antiresorptive treatment of osteoporosis in clinical practice. Their levels change 
rapidly after the start of treatment and the efficacy of therapy can be evaluated by 
bone markers in 1 to 3 months, versus1 to 2 years as regards BMD (Garnero and 
Delmas 2004). Moreover, in comparison with increases of BMD, their decreased 
levels can explain a greater part of the reduction in vertebral fracture risk in response 
to antiresorptive treatment. In randomized clinical trials this explanatory share has 
varied from from 69 to 75 % for raloxifene and from 50 % to 75 % for risedronate 
(Bjarnasson et al 2001, Cummings et al 2002, Eastell et al 2003). In the present study 
we measured the urinary N-telopeptide (NTX) of type I collagen as related to 
creatinine as a marker of cathepsin-K-mediated bone resorption, and the serum 
aminoterminal propeptide of human type I procollagen (PINP) as a marker of bone 
formation. The concentrations of both urinary NTX and serum PINP decreased 
significantly in all three groups. In the HT group the reductions were 50 % to 60 %, 
being significantly less than those of 70 to 80 % in the other groups. However, it is 
not known to what extent bone turnover rate can be safely suppressed by 
antiresorptive agents. Severe suppression of bone turnover may develop during long-
term alendronate therapy, resulting in increased susceptibility to, and delayed healing 
of pathological fractures (Odvina et al 2005). Although the co-administration of 
estrogens or corticosteroids might have been a predisposing factor, this apparent 
complication also occurred on monotherapy with alendronate (Odvina et al 2005). On 
the other hand, in risedronate-treated patients the reduction of vertebral fracture risk 
did not increase after reaching a particular threshold in the suppression of bone 
markers (Eastell 2003). This was not, however, the case for alendronate-treated 
patients, in which the greater the risk reduction, the lower the marker levels (Bauer et 
al 2004, Bauer et al 2006).   
 In terms of BMD changes, our results deviate from those of previous studies, 
which mostly have favored the combination of HT and bisphosphonate (alendronate, 
etidronate, or risedronate) over at least HT alone (Wimalawansa 1995, Harris et al 
2001). This deviation is not explained by estrogen dose, since equivalent treatments (2 
mg estradiol or 0.625 mg CEE) were used in previous studies (Bone et al 2000, Tiras 
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et al 2000, Harris et al 2001, Palomba et al 2002). As a progestin component of HT 
we used NETA, which is known to increase bone mass (Christiansen et al 1990), but 
the same regimen was used by Tiras et al (2000). In three studies (Lindsay et al 1999, 
Harris et al 2001, Greenspan et al 2003) medroxyprogesterone acetate was used and 
in two others (Bone et al 2000, Palomba et al 2002) no progestin at all was employed. 
Most importantly, however, our study was aimed at investigation of the effects of 
treatment of osteoporosis in elderly women with a mean age of 71 years, which is 10 
to 20 years higher than in earlier studies (Wimalawansa 1995, Lindsay et al 1999, 
Bone et al 2000, Tiras et al 2000, Harris et al 2001, Palomba et al 2002) except for 
that carried out by Greenspan et al (2003). It can be reasoned that our elderly subjects 
represented a group with lower bone turnover rate, which was sufficiently suppressed 
with one drug alone. Consequently, the combination did not offer any extra benefit. It 
is well known that after the first few postmenopausal years bone turnover rate goes 
down before increasing again in late senescence (Mazess 1982, Garnero et al 1994). It 
has been demonstrated that the lower the endogenous estradiol level, the higher the 
response of BMD to HT in elderly women (Rapuri et al 2004). Since serum estradiol 
concentration is inversely related to age (Rogers et al 2002) it can be anticipated that 
estrogen levels are lower in late than in early postmenopausal women. It is not clear 
why our results deviated from those of Greenspan et al (2003), who also studied 
elderly women with at mean age of 71 years. In a 3-year study they found (with 
equivalent estrogen doses) the combination therapy to be superior to HT or 
alendronate alone, and alendronate to be superior to HT in terms of BMD changes 
(Greenspan et al 2003). The number of women in the study was clearly greater than in 
ours, but women with osteopenia only were also included and the duration of the 
study was one year longer than that of the present study. 
 Collectively, our study shows HT to be as effective as alendronate alone or in 
combination with HT in increasing BMD of elderly women with osteoporosis. The 
suppression of bone turnover is somewhat less with HT only, but regarding the long-
term safety of antiresorptive treatment this may be a beneficial characteristic of the 
treatment. Using a drug combination in the treatment of osteoporosis also has an 
economic aspect, which will be finally resolved only in studies with fracture as an 
endpoint. However, treatment with alendronate has a fairly good cost-effectiveness 
ratio (Mobley et al 2006), which is strongly related to the age of the patient, with the 
cost per quality-adjusted life-years (QALYs) decreasing with advanced age 
(Stevenson et al 2005). 
 
3. Effects of hormone therapy, alendronate, and their combination on surrogate 
markers of cardiovascular diseases 
After the onset of menopause the occurrence of CVD rises and by the age of 70 years 
it is equal in women and men (Carr 2003). Women with osteoporosis are at an 
increased risk of cardiovascular events (Tanko et al 2005). Estrogen has several 
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favorable effects, that may be protective against cardiovascular diseases, the changes 
in serum lipids and lipoproteins being most widely studied (The Writing Group for the 
PEPI trial 1995, Godsland 2001, Davison and Davis 2003). The previous findings 
have suggested a protective effect of long-term HT on age-related thickening of the 
intima-media of the carotid artery (Tremollieres et al 2000, Hodis et al 2001), but in 
the elderly women with established coronary-artery atherosclerosis HT or ERT have 
had no significant effect on the progression of atherosclerosis (Hodis et al 2003). In 
recent studies no cardiovascular benefits or even adverse effects have been reported 
for HT (Grady et al 2002, Rossouw et al 2002). In the estrogen group of the WHI 
study the HR associated with CHD was non-significantly decreased (HR 0.91, 95 % 
CI 0.75-1.12), but was increased by in the estrogen-progestin group (HR 1.29, 95 % 
CI 1.02-1.63) in comparison to placebo; total CVD risk was also increased in the 
estrogen-only group by (HR 1.12, 95 % CI 1.01-1.24) (The Women's Health Initiative 
Steering Committee 2004).  
 At the vascular level, timing of the start of HT may be critical, depending on 
the stage of the atherosclerotic process. It can be speculated that before and at early 
stages of the atherosclerotic process HT might even be protective against disease 
progression, but at later stages of the process HT becomes harmful. The latest 
evidence from the WHI study showed, that for women on CEE started at the age of 50 
to 59 years, the HR for coronary events was 0.63 (95 % CI 0.36-1.08) compared with 
0.95 (95 % CI 0.79-1.16) for all women assigned to receive CEE (Hsia et al 2006). 
For some cognitive domains also, early initation of HT around menopause may be 
beneficial, while a start in late menopause may be detrimental (MacLennan et al 
2006). 
 Bisphosphonates (etidronate, pamidronate, clodronate) have been shown to 
inhibit the development of experimental atherosclerosis without altering the serum 
lipid profile, and to inhibit arterial calcification, lipid accumulation and fibrosis 
(Ylitalo 2000). These three bisphosphonates accumulate extensively in arterial walls 
and suppress macrophages in atheromatous lesions. In macrophage cultures, 
bisphosphonates inhibit the cellular accumulation and degradation of atherogenic 
LDL cholesterol and the formation of foam cells (Ylitalo 2000). Furthermore, 
etidronate has been shown to decrease the thickening of the carotid arterial wall 
(Ylitalo 2000).  
 The most powerful inflammatory surrogate marker of future cardiovascular 
risk is CRP, and it seems to have a direct proinflammatory effect (Ridker et al 1998, 
Lagrand et al 1999, Ridker et al 2000, Blake and Ridker 2001, Danesh et al 2004). 
Oral HT has been associated with increased levels of CRP (Ridker et al 1999, van 
Baal et al 1999, Luyer et al 2001, Prelevic et al 2002), whereas transdermal HT has 
had no effect (Vehkavaara et al 2001) or somewhat decreasing effect on serum CRP 
levels (Sattar et al1999). In our study elevation of the levels of CRP during oral HT 
was of the same magnitude as in previous studies (Ridker et al 1999, van Baal et al 
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1999, Luyer et al 2001, Prelevic et al 2002). It is, however, an open question whether 
the rise of CRP during HT use is a real sign of an inflammatory process in the arterial 
wall, or only a nonspecific marker of liver stimulation (Lakoski et al 2005). In our 
study the latter option was supported by simultaneous rises in the levels of serum CRP 
and SHBG, a rough marker of liver stimulation, after 6 months of HT, even though no 
significant correlation between the changes in CRP and SHBG emerged at the 
individual level.  ERT with NETA had only a minor effect on the synthesis of SHBG 
as was seen in the previous studies (Nugent et al 2003). Alendronate did not affect 
serum CRP or SHBG levels.  
Inflammation has a role in the detachment of atherosclerotic plaques that leads 
to the final occlusion of an artery. Circulating macrophages and lymphocytes become 
trapped on the vascular wall by adhesion molecules, e.g. E-selectin (Gearing and 
Newman 1993), a process which may play a role in the development of 
atherosclerosis (Farzati et al 2002). Various forms of HT are known to reduce levels 
of endothelial adhesion molecules in the peripheral blood (Cushman et al 1999, 
Farzati et al 2002), and this effect of HT has been considered protective against CVD 
(Mendelsohn and Karas1999). In our study oral HT reduced the circulating levels of 
E-selectin but alendronate did not have any effect on this marker.  
 
4. Effects of hormone therapy, alendronate, and their combination on oral health 
Early detection of tissue destruction is desirable to prevent further irreversible loss of 
connective tissue attachment of teeth and adjacent alveolar bone (Wactawski-Wende 
et al 1996, Tezal et al 2000, Wactawski-Wende 2001). Elderly women with 
osteoporosis are at an increased risk of attachment loss of teeth. The risk for HT users 
has been reported to be lower and this has been associated with higher BMD 
(Paganini-Hill 1995, Grodstein et al 1998, Krall et al 1998, Payne et al 1999, 
Reinhardt et al1999, Ronderos et al 2000, Hildebolt et al 2004). Alveolar crest height 
and alveolar bone density have been found to be higher in postmenopausal women 
receiving HT vs. placebo (Civitelly et al 2002), and severe clinical attachment loss 
(11.9 % vs.18.6 %) and alveolar bone loss (20.3 % vs. 34 %) have been reported to be 
decreased in HT users vs. non-users (Grossi 1998). Calcium and vitamin D 
supplementation also decrease alveolar bone loss (Krall et al 2001, Hildebolt et al 
2004).  
Alendronate have been shown to improve periodontal disease and to suppress 
bone turnover in postmenopausal women (Jeffcoat 1998, El-Shinnawi and El-
Tantawy 2003, Rocha et al 2004). Bisphosphonate treatment have been shown to 
improve the clinical outcome of non-surgical periodontal therapy of chronic 
periodontitis (Lane et al 2005) and it tends to promote bone formation around 
endosseous implants (Tenenbaum et al 2002). Bisphosphonates (clodronate, 
alendronate, pamidronate, zoledronate) have been shown to inhibit the catalytic 
activities of MMPs, including MMP-8, in vitro (Teronen et al 1999, Heikkilä et al 
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2002), but in the present study alendronate did not down-regulate GCF MMP-8 levels 
or expression in vivo. No effect or a slight tendency to increase GCF MMP-8 levels 
was observed. Depending on either the destructive (Sorsa et al 2004) or anti-
inflammatory role (Owen et al 2004) of MMP-8 in oral inflammation, this may even 
be useful. Estrogen has also been shown to have a dose-dependent effect on MMPs 
and it decreased MMP-1 synthesis in cultures of human osteoblastic cells (Liao and 
Luo 2001). 
In previous studies climacteric symptoms in themselves have been 
reported as risk factors of burning mouth syndrome (Tarkkila et al 2001) 
independently of HT use and non-use. Hormone therapy has been reported to 
ameliorate dry mouth feelings, which are very common in elderly women (Hakeberg 
et al 1997, Leimola-Virtanen et al 1997, Wardrop et al 1989, Friedlander 2002, 
Eliasson et al 2003). Oral dryness is the most significant oral discomfort in women in 
the menopausal period. The salivary flow rate has been shown to decrease in the 
menopausal period (women at the age of 50.7 years compared with non-menopausal 
women at the age of 42.4 years) but to increase after the start of HT with alendronate 
and calcium supplementation in younger postmenopausal women (Yalcin et al 2005). 
The authors concluded that this was the effect of HT, but they did not study the effects 
of alendronate separately. In our study the significant decrease in the mean resting 
salivary flow rate in the alendronate group was not desirable from a clinical point of 
view, because saliva is important to the health of the teeth and oral mucosa. Saliva is 
the moisturizing and lubricating component of the oral defense system and a decrease 
in its secretion is often reflected in symptoms of dry and burning mouth, and oral 
yeast infections (Pajukoski et al 2001).  In the present study, however, no difference 
was observed between the study groups in the numbers of subjects with mucosal 
pathology or positive yeast counts, or in the numbers of women reporting or not 
reporting disturbing mouth symptoms. In the HT group a trend was seen towards a 
less frequent positive yeast count but this difference was not statistically significant. 
The discrepancy between the present and previous studies might in part be due to the 
higher age of the present subjects. 
Salivary protein analyses can be used to measure serum-derived proteins in 
saliva as markers of the integrity of mouth mucosa, with very small amounts of these 
proteins being detected in the saliva in healthy subjects (Laine et al 1992, Pajukoski et 
al 1997, Meurman et al 1998). Treatment with HT and alendronate, alone or in 
combination, had no effect on oral mucosa in this regard. 
Collectively, the only significant finding in this part of our study was the 
reduced resting saliva flow rate in the alendronate-treated women. Limitations were 
the small number of participants and the relatively high drop-out rate. Therefore, the 





5. Effect of hormone therapy on the health-related quality of life  
We used the 15D questionnaire to measure HRQoL. It is a generic, comprehensive, 
15-dimensional, standardized, self-administered measure of HRQoL that can be used 
both as a profile and a single index score measure. In an earlier study of women 
younger than those in the present trial (mean age of 62 years) the 15D questionnaire 
worked as well as the Nottingham Health Profile (NHP) in showing a positive impact 
of HT (continuously combined estradiol valerate [E2V] plus medroxyprogesterone 
acetate [MPA] for 6 years) on HRQoL in comparison with age-matched non-users. 
All six dimensions of the NHP and 13 of the 15 dimensions of the 15D questionnaire 
were improved, with a clinically significant (>0.03) difference of 0.044 in the general 
15D score (Sintonen et al 2003). Other questionnaires such as RAND-36, SF-36, SIP 
and EQ-5D have also been used to measure quality of life related to HT. 
         The positive effects of HT on climacteric symptoms are well documented. The 
impact of HT on generic HRQoL has not been so widely studied, but the results have 
been promising in early menopause (Wiklund et al 1992, Zethraeus et al 1997, 
Genazzani et al 2002). In women with a mean age of 53 years, four months’ treatment 
with transdermal estrogen combined with MPA for 14 days per month brought an 
improvement in all dimensions of the NHP, especially the dimensions of sleep and 
energy (Wiklund et al 1992). Low-dose continuously combined HT also improved 
HRQoL (measured by means of the 15D questionnaire) of younger postmenopausal 
women (mean 56 years) for whom the relief of menopausal symptoms was the 
objective of treatment (Ylikangas et al 2005). In a cross-sectional study HT users 
scored better than non-users in most dimensions of HRQoL measured by means of 
SF-36 and EQ-5D questionnaires, but women of 55 years or older (41 % of HT users 
and 38 % of non-users) reported lower scores relative to the physical domains, but 
higher scores in the mental domains as opposed to the younger women. It was also 
found that QoL was mainly influenced by socio-economic and cultural factors 
(Genazzani et al 2002). 
The women in the above mentioned studies were significantly younger than 
in our study. Women are expected to spend around one-third of their lives in the 
postmenopausal state, and up to 25 % of elderly women who have been 
postmenopausal for more than 10 years still suffer from moderate or severe 
climacteric symptoms (Oldenhave et al 1993, Zichella 1993). In our study 4 % of HT 
users and 7 % of non-users still had hot flushes at least some of the time, and there 
was a statistically significant difference in the occurrence of these symptoms between 
the groups. However, we did not include hot flushes as an explanatory variable in our 
model, since it is a somewhat dependent variable, the effect of which should be 
incorporated in the 15D score.  
Postmenopausal women, making a decision on whether or not to use HT, may 
consider well-being to be a more important factor than the reported health risks 
 62
(HERS; WHI) (Hlatky et al 2002, Hays et al 2003). Nevertheless, in recent trials, the 
impact of HT on quality of life has remained unclear. In the WHI trial women 
assigned to use HT (mean age 63 years) experienced fewer sleep disturbances, better 
physical functioning and less bodily pain than women who were assigned to use 
placebo (RAND-36). The difference was statistically, but not clinically significant at 
one year of treatment, but it disappeared with continuation of treatment for an 
additional two years (Hays et al 2003). In the WHI estrogen-only group CEE had no 
clinically meaningful effect on HRQoL; one year of treatment with CEE produced a 
significant small reduction in sleep disturbances but a significant small negative effect 
on social functioning (Brunner et al 2005). 
The HERS trial showed mixed effects. Women without hot flushes at entry 
showed declines in physical measures and those with hot flushes showed 
improvement in emotional measures when assigned to HT (mean age of 67 years). 
HRQoL, measured by means of several questionnaires (RAND, depressive symptoms 
on the Burnam screening scale), was impaired in older women and in those with 
chronic diseases (diabetes, hypertension, chest pain, heart failure). The negative 
effects of these factors on QoL outweighed the positive impact of HT (Hlatky et al 
2002), as did chronic diseases and concomitant medication in the present study.  
In the WHI study relief of climacteric symptoms with HT was not associated 
with improvement in HRQoL during the three years (Hays et al 2003). In our cross-
sectional study, HT users reported fewer hot flushes than the non-users, as expected, 
but their general HRQoL was not clinically better. Our study showed that elderly HT 
users were better off in the dimensions of usual activities, vitality and sexual activity 
than non-users, but the clinical relevance of this finding might be poor. For example, 
in terms of sexual activity the difference found originated from four percent of 
estrogen users being one out of 5 levels better off than non-users.  
A limitation of our study is its cross-sectional nature, implying that the 
groups of estrogen users and non-users were not assigned randomly. To control for or 
at least alleviate the possible selection effect, the Tobit regression model was used to 
standardize the groups in terms of important background and clinical characteristics 
such as age, education, number of medications and chronic diseases. The results 
suggest that education has a non-significant positive and the number of medication, 
and chronic diseases, a statistically significant negative effect on HRQoL, but the 
effect of age, against expectations, non-significant. Obviously the number of types of 
medication and diseases, detract from the independent significance of age, since they 
are age-related variables. This turned indeed to be the case, since in a model where the 
number of types of medication and the number of diseases were removed, the 
coefficient of age was highly significant (p=0.0001).  
In our study HT users were more educated and healthier in terms of the 
number of concomitant chronic diseases and medication, which might cause a healthy 
user bias as seen in previous observational studies. The use of antidepressants did not 
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differ between the groups. Therefore, modeling was used to control for or at least 
alleviate such a bias. Inferring from the facts of no difference in use of 
antidepressants, and level value on the 15D dimension of depression estrogen 
deficiency does not seem to increase the susceptibility to depression in this age group. 
Collectively, in this population-based study, HT seemed to improve the 
HRQoL of elderly postmenopausal women slightly in the dimensions of usual 
activities, vitality and sexual activity, but the overall improvement in HRQoL was 
neither statistically significant nor clinically important. 
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Summary and Conclusions 
We randomized 90 elderly osteoporotic women between 65 and 80 years of age to 
receive HT (a continuous combination of oral estradiol plus NETA) or alendronate or 
their combination for two years and compared the treatments with regard to their 
effects on bone mineral density and turnover, two surrogate markers of risk of 
cardiovascular diseases, CRP and E-selectin, as well as oral health. 
 All the treatments increased BMD at the lumbar spine and the upper femur to 
a similar extent, with the combination not offering an extra gain. Bone turnover rate 
was decreased less by HT than by alendronate alone or the combination, but the 
optimum for the suppression of bone turnover during antiresorptive therapy is 
unknown  
 HT but not alendronate increased serum CRP concentrations but the 
simultaneous rise in serum SHBG levels suggested the change to be a sign of 
unspecific stimulation of hepatic protein synthesis by estrogens. HT but not 
alendronate decreased serum E-selectin levels, which may reflect a direct positive 
effect of HT on endothelial cells. Alendronate did not block the effect of HT on these 
surrogate markers in the combination group.  
 Alendronate caused a decrease in the resting salivary flow rate and tended to 
increase GCF MMP-8 levels. Otherwise, the treatments had no effect on oral health 
parameters, but firm conclusions were limited by a low participation rate and a high 
drop-out rate in this part of the study. 
 In the population-based cohort of 1663 postmenopausal women aged 65-70 
years, 585 women were estrogen users and 1078 were non-users. Measured by means 
of the 15D questionnaire, HT seemed to improve the HRQoL of elderly 
postmenopausal women significantly in the dimensions of usual activities, vitality and 
sexual activity, but the overall improvement in HRQoL was neither statistically 
significant nor clinically important. 
 In elderly postmenopausal women HT is an effective alternative to treat 
osteoporosis, but not to improve quality of life or oral health. It has divergent effects 
on markers of the risk of cardiovascular diseases. Given all the potential risks of 
coronary heart disease, stroke, thromboembolic events and cancer associated with HT, 
bisphosphonates might be the first option to start the treatment of postmenopausal  
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QUALITY OF LIFE QUESTIONNAIRE (15D©) 
 
Please read through all the alternative responses to each question before placing a cross (x) against the 
alternative which best describes your present health status. Continue through all 15 questions in this 
manner, giving only one answer to each. 
QUESTION 1.  MOBILITY 
1 (  ) I am able to walk normally (without difficulty) indoors, outdoors and on stairs. 
2 (  ) I am able to walk without difficulty indoors, but outdoors and/or on stairs I have slight difficulties. 
3 (  ) I am able to walk without help indoors (with or without an appliance), but outdoors and/or on 
stairs only with considerable difficulty or with help from others.  
4 (  ) I am able to walk indoors only with help from others.  
5 (  ) I am completely bed-ridden and unable to move about. 
QUESTION 2.  VISION 
1 (  ) I see normally, i.e. I can read newspapers and TV text without difficulty (with or without glasses).  
2 (  ) I can read papers and/or TV text with slight difficulty (with or without glasses).  
3 (  ) I can read papers and/or TV text with considerable difficulty (with or without glasses). 
4 (  ) I cannot read papers or TV text either with glasses or without, but I can see enough to walk 
about without guidance.  
5 (  ) I cannot see enough to walk about without a guide, i.e. I am almost or completely blind. 
QUESTION 3.  HEARING 
1 (  ) I can hear normally, i.e. normal speech (with or without a hearing aid). 
2 (  ) I hear normal speech with a little difficulty. 
3 (  ) I hear normal speech with considerable difficulty; in conversation I need voices to be louder than 
normal. 
4 (  ) I hear even loud voices poorly; I am almost deaf. 
5 (  ) I am completely deaf. 
QUESTION 4.  BREATHING 
1 (  ) I am able to breathe normally, i.e. with no shortness of breath or other breathing difficulty. 
2 (  ) I have shortness of breath during heavy work or sports, or when walking briskly on flat ground or 
slightly uphill. 
3 (  ) I have shortness of breath when walking on flat ground at the same speed as others my age. 
4 (  ) I get shortness of breath even after light activity, e.g. washing or dressing myself. 
5 (  ) I have breathing difficulties almost all the time, even when resting. 
QUESTION 5.   SLEEPING 
1 (  ) I am able to sleep normally, i.e. I have no problems with sleeping. 
2 (  ) I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes waking at night. 
3 (  ) I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not slept enough. 
4 (  ) I have great problems with sleeping, e.g. having to use sleeping pills often or routinely, or usually 
waking at night and/or too early in the morning. 
5 (  ) I suffer severe sleeplessness, e.g. sleep is almost impossible even with full use of sleeping pills, 
or staying awake most of the night.      
QUESTION 6.   EATING 
1 (  ) I am able to eat normally, i.e. with no help from others. 
2 (  ) I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with special 
appliances). 
3 (  ) I need some help from another person in eating. 
4 (  ) I am unable to eat by myself at all, so I must be fed by another person. 
5 (  ) I am unable to eat at all, so I am fed either by tube or intravenously.  
QUESTION 7.  SPEECH 
1 (  ) I am able to speak normally, i.e. clearly, audibly and fluently. 
2 (  ) I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or changes of 
pitch. 
3 (  ) I can make myself understood, but my speech is e.g. disjointed, faltering, stuttering or 
stammering. 
4 (  ) Most people have great difficulty understanding my speech. 
5 (  ) I can only make myself understood by gestures. 
QUESTION 8.   ELIMINATION 
1 (  ) My bladder and bowel work normally and without problems. 
2 (  ) I have slight problems with my bladder and/or bowel function, e.g. difficulties with 
urination, or loose or hard bowels. 
3 (  ) I have marked problems with my bladder and/or bowel function, e.g. occasional                   
 'accidents', or severe constipation or diarrhea. 
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4 (  ) I have serious problems with my bladder and/or bowel function, e.g. routine 'accidents', 
or need of catheterization or enemas. 
5 (  ) I have no control over my bladder and/or bowel function. 
QUESTION 9.   USUAL ACTIVITIES 
1 (  ) I am able to perform my usual activities (e.g. employment, studying, housework, free-
time activities) without difficulty. 
2 (  ) I am able to perform my usual activities slightly less effectively or with minor 
difficulty. 
3 (  ) I am able to perform my usual activities much less effectively, with considerable 
difficulty, or not  completely. 
4 (  ) I can only manage a small proportion of my previously usual activities.  
5 (  ) I am unable to manage any of my previously usual activities. 
QUESTION 10.  MENTAL FUNCTION 
1 (  ) I am able to think clearly and logically, and my memory functions well 
2 (  ) I have slight difficulties in thinking clearly and logically, or my memory sometimes 
fails me.   
3 (  ) I have marked difficulties in thinking clearly and logically, or my memory is somewhat 
impaired. 
4 (  ) I have great difficulties in thinking clearly and logically, or my memory is seriously 
impaired. 
5 (  ) I am permanently confused and disoriented in place and time. 
QUESTION 11.   DISCOMFORT AND SYMPTOMS 
1 (  )  I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.  
2 (  )  I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.  
3 (  )  I have marked physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
4 (  )  I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
5 (  )  I have unbearable physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
QUESTION 12.   DEPRESSION 
1 (  )  I do not feel at all sad, melancholic or depressed. 
2 (  )  I feel slightly sad, melancholic or depressed. 
3 (  )  I feel moderately sad, melancholic or depressed. 
4 (  )  I feel very sad, melancholic or depressed. 
5 (  )  I feel extremely sad, melancholic or depressed. 
QUESTION 13.   DISTRESS 
1 (  )  I do not feel at all anxious, stressed or nervous. 
2 (  )  I feel slightly anxious, stressed or nervous. 
3 (  )  I feel moderately anxious, stressed or nervous. 
4 (  )  I feel very anxious, stressed or nervous. 
5 (  )  I feel extremely anxious, stressed or nervous. 
QUESTION 14.   VITALITY 
1 (  )  I feel healthy and energetic. 
2 (  )  I feel slightly weary, tired or feeble. 
3 (  )  I feel moderately weary, tired or feeble. 
4 (  )  I feel very weary, tired or feeble, almost exhausted. 
5 (  )  I feel extremely weary, tired or feeble, totally exhausted. 
QUESTION 15.  SEXUAL ACTIVITY 
1 (  )  My state of health has no adverse effect on my sexual activity. 
2 (  )  My state of health has a slight effect on my sexual activity. 
3 (  )  My state of health has a considerable effect on my sexual activity.  
4 (  )  My state of health makes sexual activity almost impossible.  
5 (  )  My state of health makes sexual activity impossible. 
 
 
